Rick Simpson Oil (RSO) inna Jamaica: Di Complete Guide by OilWell Cannabis

Understanding Rick Simpson Oil Through a Jamaican Lens

Who Rick Simpson Be?

Rick Simpson born 1949 inna Amherst, Nova Scotia, Canada — a working-class tradesman, not no doctor or scientist. Him story beat deep wid weh we see all cross Jamaica: everyday people a search fi healing when di regular medicine nuh mek it. Inna 1997, while him a work a hospital inna Moncton, Simpson get serious head injury from scaffolding fall. Di aftereffect lef him wid persistent tinnitus, dizziness, en post-concussion symptoms weh doctors couldn’t fix. Di medication dem prescribe either fail fi help or mek him condition worse. When ganja provide more relief dan anything him physicians offer, him doctor refuse fi support it. Sound familiar? Nuff Jamaicans know dis pattern too well — di system a fail, en haffi find unnu own way forward.

Simpson interest inna concentrated cannabis oil deepen after him learn bout a 1974 NIH-funded study a Medical College of Virginia, weh THC report seh it slow down tumor inna mice. Dat study — intend fi demonstrate harm — become foundational reference fi Simpson, even though its findings never replicate inna controlled human cancer trials. Dis a di same kind a early research weh spark curiosity all throughout Jamaica ganja culture fi decades.

Di pivotal moment come inna 2003. Simpson report seh three bump pon him arm get diagnose as basal cell carcinoma. Rather dan pursue conventional treatment, him apply concentrated cannabis oil direct to di lesions, cover dem wid bandage, en claim dem disappear within four days. No independent medical verification ever publish. No biopsy confirmation. No clinical follow-up inna any peer-reviewed source. Yet dis personal experience become di origin story a Rick Simpson Oil.

Important context fi wi Jamaican community: Simpson account a personal testimony, not medical evidence. Di absence a clinical documentation mean dem events cyan evaluate as scientific proof. But dem historically significant as di catalyst fi a global movement — one weh reach Jamaica shore long before legalization talk start yah. Wi respect Simpson story while committing to di evidence standards Jamaicans deserve.

Di Crusade — Spreading Di Oil

After him 2003 experience, Simpson commit himself to producing en distributing concentrated cannabis oil from him property inna Maccan, Nova Scotia. Him give it weh free to cancer patients en others inna him community. Him charge nothing. By him account, him help dozens a people wid conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, en more.

Simpson story reach global audience through di 2005 documentary Run From The Cure, weh become one a di most widely shared ganja advocacy films a fi dem era. Within cannabis communities worldwide — including Jamaica deep-rooted ganja culture — it was foundational. Fi many, Run From The Cure was dem first introduction to concentrated cannabis oil as medicine.

Simpson advocacy bring him into direct conflict wid Canadian law. Di RCMP raid him property inna 2005 en again inna 2009. Him get charge wid cultivation, possession, en trafficking. Facing continued legal pressure, Simpson eventually lef Canada fi Europe, continuing him advocacy from abroad. Dis pattern a criminalization mirror weh ganja farmers en healers face inna Jamaica fi generations — punish fi a plant di world was only beginning fi understand.

Inna 2012, Simpson publish Phoenix Tears: The Rick Simpson Story en maintain phoenixtears.ca as him advocacy platform. Him remain consistent en uncompromising: cannabis oil could cure cancer, en pharmaceutical companies, governments, en medical institutions was suppressing dis knowledge.

Important context fi Jamaican readers: Simpson conspiratorial framing reflect a worldview shared by many inna di early cannabis movement. Wi present it yah not fi endorse or dismiss it, but fi understand why RSO become culturally significant. Jamaica own history wid cannabis prohibition en spiritual suppression give wi unique insight into dis distrust a institutions. Di evidence-based assessment a him medical claims follow below — because unnu deserve honesty, not hype.

Di Traditional RSO Protocol — Simpson 60-Gram, 90-Day Regimen

Simpson core recommendation was structured oral protocol: consume 60 grams a concentrated cannabis oil over approximately 90 days. Him describe dis as a cancer treatment protocol, though him recommend it fi numerous conditions. Yah di detailed breakdown:

Goal

Consume 60 grams a concentrated, high-THC cannabis oil over roughly 90 days. Simpson consider dis di minimum fi serious cancer treatment.

Titration Schedule

• Week 1: Begin wid a dose di size a half a grain a dry rice — bout 10-15 mg a oil — three times daily. Total daily intake: 30-45 mg. Di goal a fi mek di body adjust to THC psychoactive effects.
• Weeks 2-5: Double di dose every four days. By week five, reach approximately 1 gram (1,000 mg) a oil per day, divided into three doses.
• Weeks 5-12: Maintain 1 gram per day, divided into three 333 mg doses, until all 60 grams consume.

Administration Methods

• Primary — oral: Place under tongue or swallow. Simpson consider dis di most important route fi systemic absorption en internal cancers.
• Secondary — topical: Fi skin cancers, apply directly to lesions, cover wid bandage, change every 3-4 days. Combine wid oral dosing.
• Not recommended as primary — inhalation: Simpson acknowledge smoking or vaporizing fi immediate symptom relief (pain, nausea) but maintain oral route was necessary fi sustained, high-dose exposure.

Tolerance en Psychoactive Effects

• Simpson claim patients develop THC tolerance within 3-4 weeks.
• Him consider euphoria, sedation, or disorientation minor en temporary side effects.
• Recommend initial doses at night fi sleep through early psychoactive effects.
• Warn against driving or operating machinery during titration.

Post-Protocol Maintenance

After completing 60 grams, Simpson recommend 1-2 grams per month indefinitely fi long-term health en cancer prevention.

Dietary en Lifestyle Recommendations

Simpson advocate reducing sugar, avoiding processed foods, en improving nutrition — though him dietary advice was secondary en general compared to him detailed oil protocol.

Important Context fi Jamaican Patients
Dis protocol design by one person based on personal experience. It nuh develop through clinical trials, dose-finding studies, or formal research. Critical points:

• No controlled trial validation. No publish randomized controlled trials, cohort studies, or well-documented case series evaluate dis specific 60-gram/90-day protocol fi any cancer type or condition.
• Assume crude, unstandardized material. Di 60-gram quantity assume single-strain, THC-dominant extract wid no standardized potency. Actual THC content vary wild.
• Very high THC exposure. At peak dosing, patients consume roughly 1 gram a high-THC oil daily. Assuming 60-90% THC, dat a 600-900 mg a delta-9 THC per day — far exceeding anything study clinically. Di FDA-approved synthetic THC drug dronabinol typically dosed at 2.5-20 mg per day.
• Real risks at dese doses. Consuming 600-900 mg THC daily carry serious risks: severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, en cannabis use disorder. Dese well-documented inna di research wi discuss later.
• Oncology context. Patients wid active cancer medically complex. Using unregulated, unstandardized cannabis oil as primary treatment — potentially in place a proven therapies — introduce harm beyond di oil itself.

What Traditional RSO Was — Di Product

Traditional RSO refer to di specific oil Simpson make en advocate fi, defined by him method en materials:

Source Material

Simpson use high-THC, indica-dominant cannabis strains. Him favor heavy, sedating indica genetics en recommend against sativa fi cancer treatment. Him grow him own or source from trusted growers. Deh was no strain standardization — material vary by availability en season.

Extraction Solvent

Simpson originally use naphtha (petroleum-based lighter fluid) or 99% isopropyl alcohol. Him warn against butane or acetone. Neither naphtha nor isopropyl alcohol is food-grade. Naphtha may contain benzene, toluene, xylene, en other toxic or carcinogenic compounds. Incomplete solvent purging — difficult fi verify without lab testing — lef potentially harmful residues.

Extraction Process

1. Dry cannabis inna bucket
2. Cover wid solvent, agitate fi dissolve cannabinoids
3. Filter solvent through cheesecloth into collection vessel
4. Repeat wid fresh solvent
5. Evaporate solvent inna rice cooker at low heat
6. Thick, dark oil remain at bottom
7. Transfer to oral syringes fi storage en dosing

Di rice cooker maintain temperature dat evaporates solvent without excessive cannabinoid degradation — but it still high enough fi decarboxylate THCa into THC en destroy most volatile terpenes.

Appearance en Physical Characteristics

Traditional RSO was extremely dark — nearly black — thick, viscous, tar-like oil wid strong cannabis odor en possible solvent-residual smell. Sticky en difficult fi handle at room temperature, more fluid when warm.

Cannabinoid Profile

• Primarily decarboxylated delta-9 THC. Heat converted essentially all THCa to delta-9 THC. Traditional RSO was activated, THC-dominant.
• Naturally occurring minor cannabinoids. Whatever CBD, CBN, CBC, CBG di source strain contain were present at natural ratios — not controlled, measured, or targeted.
• No ratio control. Profile entirely determined by genetics en growing conditions.
• Estimated THC content. Depending on starting material, likely 60-90% total THC by weight — never lab-verified inna traditional production.

Terpene Content

Minimal to none. Solvent extraction dissolve terpenes along wid cannabinoids, en high-heat evaporation volatilize terpenes at temperatures well below cannabinoid degradation thresholds. Traditional RSO effectively strip a terpene content.

Standardization en Testing

None. Every batch different. No Certificate of Analysis, no cannabinoid quantification, no contaminant screening. Simpson operate before cannabis legalization en standardized lab-testing infrastructure.

Residual Solvent Risk

Dis one a di most significant safety concerns. Naphtha en isopropyl alcohol not food-grade. Incomplete purging lef potentially harmful residues. Modern extraction use food-grade ethanol or supercritical CO₂ specifically fi address dis.

What Dis Mean fi Jamaica
Many products sold as “RSO” inna Jamaica today bear likkle resemblance to what Simpson originally make. Di term become generic. If unnu buying RSO inna Kingston, Montego Bay, or from local producers inna di Blue Mountains, unnu need fi know: traditional RSO had no standardization, no testing, destroy terpenes, en carry solvent risks. Di modern evolution matter fi unnu safety.

Simpson Claims vs. Di Evidence

Rick Simpson mek expansive therapeutic claims: RSO could cure cancer en was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, en more. Him was adamant, consistent, en public bout dese claims throughout him advocacy career.

Mek wi evaluate dese against actual evidence, using di same standards wi apply to wi own products.

What Simpson Was Not

Simpson was not a scientist, physician, pharmacologist, or researcher. Him had no formal training inna medicine, oncology, pharmacology, or clinical research methodology. Him never design, conduct, fund, or publish a clinical trial. Him never submit results to peer review. Him evidence base consist a personal experience, self-reported patient outcomes, en informal testimonials — wid no controls, no independent verification, no imaging confirmation, no long-term follow-up, no blinding.

What Di Preclinical Literature Show

Di preclinical cannabinoid-cancer literature do exist en scientifically interesting:

• In vitro studies demonstrate THC en CBD can induce apoptosis (programmed cell death), inhibit proliferation, en reduce angiogenesis inna certain cancer cell lines
• Animal model studies show some tumor-growth inhibition inna mice en rats treated wid cannabinoids
• Dese findings generate legitimate scientific interest en ongoing research

What Di Preclinical Literature DO NOT Show

• Dese findings nuh translate into proven human cancer cures. Di gap between in vitro or animal results en human clinical outcomes vast, well-documented across all oncology research.
• No human clinical trial demonstrate dat RSO or any cannabis oil preparation cure cancer.
• Several small human trials a cannabinoids inna cancer contexts (particularly glioblastoma) conduct, but dem exploratory, small, en nuh produce results supporting cancer-cure claims.

Institutional Positions

• U.S. National Cancer Institute (NCI): Acknowledge cannabinoids study fi potential anticancer effects inna laboratory en animal models but nuh endorse cannabis or cannabis oil as cancer treatment.
• U.S. Food en Drug Administration (FDA): Nuh approve any cannabis plant product fi cancer treatment. Di only FDA-approved cannabinoid-related products dem fi specific indications: Epidiolex (CBD) fi certain seizure disorders, en dronabinol/nabilone (synthetic THC analogues) fi chemotherapy-related nausea en AIDS-related wasting.
• Health Canada: Never approve RSO or cannabis oil as cancer cure.
• NCCIH: Explicitly state strongest cannabinoid evidence is fi rare epilepsies, chemo nausea/vomiting, en HIV/AIDS appetite — not cancer cure.

What Simpson Get Right

Simpson draw attention to cannabinoids as serious biomedical research area when most a di world was ignoring or suppressing dat conversation. Him advocacy — however scientifically imprecise — help create di political, cultural, en social conditions fi di legal cannabis industry en research infrastructure dat exist today. Him was among di first fi bring concentrated cannabis oil to widespread public awareness, en di term RSO remain di most recognized name fi full-spectrum cannabis extract.

What Him Overstate

Di leap from preclinical signals to cancer cure was not support by human evidence when Simpson mek it, en it not support now. Encouraging patients — particularly cancer patients — fi rely pon RSO as primary treatment in place a proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carry genuine harm potential. Delayed or foregone treatment fi treatable cancers a documented concern inna alternative medicine. Simpson absolute certainty bout curative claims exceed what di evidence could support en still exceed it today.

Di Legacy en Evolution

Di term RSO nowadays use broadly en loosely across di legal cannabis industry. Many products label RSO bear likkle resemblance to Simpson original method. Simpson himself critical a commercial products dat use di RSO name while departing from him philosophy — him give oil weh free en urge people fi mek dem own rather dan buy from companies.

Dis philosophical tension real. Simpson model was anti-commercial, DIY, free-access. Di modern industry commercialize, standardize, en regulate what him distribute freely. Whether dat improvement (quality control, lab testing, dosing precision) or betrayal (profit extraction, regulatory gatekeeping) depend pon perspective. Di cannabis community remain divided.

What not in dispute: modern RSO evolve substantially. Dem changes directly relevant to what wi offer Jamaican patients today.

Traditional RSO vs. Modern Formulated RSO

Dimension	Traditional RSO	OilWell Formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% wid defined seven-terpene profile
Standardization	None — every batch different	Lab-tested wid specific mg/mL targets
Lab testing	Not available or performed	Full panel testing
Residual solvents	Significant risk wid naphtha	Controlled en tested
Dosing precision	Approximate, syringe-based	Measured per mL (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil en vape cartridge
THCa preservation	No — fully decarboxylated by heat	Yes — THCa included as separate ingredient at 1,500mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why Wi Formulas Diverge From Traditional RSO

Wi deliberately depart from traditional RSO inna evidence-motivated ways:

Multi-cannabinoid approach: Traditional RSO rely pon whatever single strain di maker grow. Wi formulas intentionally include seven cannabinoids because entourage-effect literature suggest potential benefit from cannabinoid diversity, even though robust clinical proof a whole-formula synergy remain limited.

Terpene preservation en addition: Traditional RSO had essentially no terpenes due to solvent en heat destruction. Wi include live terpenes at 5% wid seven specific terpenes because terpene bioactivity plausible en support at preclinical levels.

THCa as separate ingredient: Traditional RSO fully decarboxylate everything. Wi sublingual formula include 1,500mg THCa as distinct ingredient, preserving di acidic precursor because THCa literature suggest potentially relevant non-psychoactive bioactivity lost during conversion.

Reduced delta-9 THC dominance: Traditional RSO was 60-90% delta-9 THC. Wi sublingual formula use only 90mg delta-9 THC while distributing content across CBD (4,500mg), CBG (3,000mg), delta-8 THC (6,000mg), CBN (750mg), en CBC (750mg). Dis reflect broader cannabinoid research rather dan single-compound dominance.

Product format innovation: Simpson envision only oral oil from syringe. Wi offer both 30mL sublingual oil en 1-gram vape cartridge, each wid format-specific formulation acknowledging different pharmacokinetic profiles.

Solvent Safety en Extraction Evolution

Traditional RSO use naphtha or isopropyl alcohol — neither food-grade. Naphtha is petroleum-based en may contain benzene, toluene, xylene. Incomplete purging leave harmful residues.

Modern cannabis extraction use food-grade ethanol or supercritical CO₂. Dese allow more complete solvent removal, en finished products can be test fi residual solvents using validated analytical methods like headspace gas chromatography. Dis one a di most straightforward improvements di modern regulated industry mek over traditional RSO.

Di Decarboxylation Question

Traditional RSO fully decarboxylated. Rice cooker heat (60-80°C fi naphtha, ~82°C fi isopropyl) converted essentially all THCa to delta-9 THC. Dis meant acidic cannabinoids inna raw cannabis lost.

Wi sublingual formula deliberately preserve 1,500mg THCa as distinct ingredient. Dis intentional formulation choice informed by THCa evidence showing potential anti-inflammatory activity via COX-2 inhibition en neuroprotective potential via PPARγ agonism — bioactivity lost when THCa convert to THC.

Terpene Loss inna Traditional RSO

Terpenes volatile aromatic compounds wid low boiling points (21-157°C). Traditional RSO destroy terpenes inna two ways: dissolve dem into solvent wash, den evaporate dem during high-heat removal. Whatever aromatic or potentially bioactive terpenes di source cannabis contain, dem lost.

Wi formulas specify live terpenes at 5% wid defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, en terpinolene. Each have evidence profile inna wi GENERAL KNOWLEDGE section. Entourage-effect literature provide theoretical framework fi why preserving terpenes alongside cannabinoids may matter pharmacologically.

Evidence Standards Den en Now

Rick Simpson operate inna pre-legalization, pre-lab-testing era. When him begin inna early 2000s, cannabis illegal inna Canada en most a di world. No regulatory framework, no standardized testing, no legal pathway fi clinical research, no peer-reviewed journals dedicate to cannabis therapeutics. Di underground was di only access point, personal experience di primary evidence currency.

Simpson methods reflect dem constraints. Him evidence was anecdotal, production unstandardized, claims untested inna any formal sense. Dis not necessarily moral failing — it description a him environment.

Dis document tek fundamentally different approach. Wi GENERAL KNOWLEDGE section apply formal evidence hierarchy: human clinical evidence first, den systematic reviews, institutional summaries, den preclinical literature. Every compound-level claim tie to specific peer-reviewed sources wid evidence strength clearly labeled. Wi honor RSO historical origin while committing to modern cannabinoid science standards. Where Simpson rely pon personal testimony, wi rely pon published literature en institutional sources.

Simpson Protocol vs. Modern Dosing

Simpson 60-gram/90-day protocol design around crude, single-strain, THC-dominant extract wid no standardized potency. Direct comparison between him dosing en wi modern, standardized, multi-cannabinoid formulation nuh straightforward — di products fundamentally different.

Key differences:

• Cannabinoid concentration: Wi sublingual formula deliver 553mg a total active cannabinoids per mL across seven defined compounds. Traditional RSO potency unknown en variable.
• Cannabinoid ratios: Simpson oil was 60-90% delta-9 THC. Wi formula distribute 16,590mg total cannabinoids across CBD (4,500mg), CBG (3,000mg), delta-8 THC (6,000mg), THCa (1,500mg), delta-9 THC (90mg), CBN (750mg), en CBC (750mg) — completely different pharmacologic profile.
• Terpene presence: Simpson oil had no terpenes. Wi formula include live terpenes at 5%, weh may influence absorption, effect, en tolerability.
• Delta-9 THC exposure: Simpson protocol at peak dosing deliver ~600-900mg delta-9 THC per day. Wi sublingual formula contain only 90mg delta-9 THC inna entire 30mL bottle (3mg per mL), making per-dose exposure dramatically lower.

Wi dosing guidance develop independently a Simpson protocol, informed by per-compound evidence inna GENERAL KNOWLEDGE section en responsible titration principles accounting fi each individual cannabinoid safety profile.

Bout OilWell Cannabis en Wi RSO Formula

Wi Origin Story

OilWell Cannabis found by Colin Valencia inna Houston, Texas. Colin grow up inna McAllen, Texas — right cross di river from Reynosa, Tamaulipas, Mexico. Di McAllen-Reynosa area, known as di Borderplex, a one a di most economically challenged en dangerous regions along di U.S.-Mexico border. Dis background shape Colin understanding a suffering, accessibility, en resilience — values dat resonate across Jamaica own communities facing economic hardship en systemic challenges.

Colin childhood mark by exposure to both opportunities en dangers a border life. Early on, him learn fi hustle, tek on risky work transporting items cross di border fi various groups. Dem experiences expose him to complexities en dangers. Nuff a him best friends get kill or deh inna prison because a associated dangers. Him face every form a violence imaginable, both inna streets en cross border. By sixteen, him haffi lef home fi good.

Despite dangers, Colin nuh fall into darkest paths like selling harder substances. Instead, him focus pon cannabis, seeing it as safer en more beneficial alternative. Him grow up inna traditional cannabis world long before legalization, learning di plant intimately while operating inna shadows. Over time, him transition from early risky ventures to creating legal, legitimate business inna industry him believe in.

Colin later become formally train software engineer en do custom development work fi Baylor College of Medicine, one a most prestigious medical institutions inna Texas Medical Center. Dat combination — deep cannabis plant knowledge plus medical-grade technical precision — define wi approach.

Bentley Story — Wi True Beginning

Wi company origin begin wid a dog name Bentley. Bentley was more dan pet — him was family, companion who stand by Colin through toughest times. When Bentley fall seriously ill, veterinarians deliver verdict no pet owner want: euthanasia was only humane option. Bentley paralyze inna back legs. Dem seh pain medications would destroy him internal organs, causing more suffering. Choice was painful prolonged decline or immediate mercy killing.

But giving up pon Bentley never option. Colin already face too much loss en see too much suffering. Bentley was fighter, just like him. Inna desperate search fi alternatives, Colin stumble pon CBD healing properties through question dat change everything.

A kind-hearted rescue worker name Jessica ask: “You’ve moved how many tons a weed en you’ve never heard a CBD?”

Colin had cannabis experience — but recreational. Him’d never explore therapeutic applications. Jessica question expose blind spot dat become mission.

Determined fi save Bentley, Colin learn fi create CBD golden paste — specialized cannabinoid formula fi pets. It wasn’t cure, but it was lifeline en hope. En dat hope deliver what veterinary medicine seh was impossible: Bentley get up. Him walk over to Colin en bring him ball fi play. Dis was not placebo effect — dogs nuh respond to placebo. Dis was cannabinoid medicine doing what pharmaceuticals could not.

Bentley live another ten years, passing naturally at age twenty. During dem ten years, Colin develop specialized cannabis formulas fi every age-related condition Bentley face:

• Neurodegeneration lead to understanding CBG neuroprotective properties en THCa PPARγ agonism fi brain cell protection
• Dementia lead to CBC role inna neurogenesis
• Glaucoma lead to THC CB1 agonism fi intraocular pressure reduction
• Crippling arthritis lead to multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, en beta-caryophyllene working through different receptor systems simultaneously

Single cannabinoids nuh enough. Bentley evolving conditions require multi-cannabinoid synergy. Pharmaceutical precision matter — Bentley life depend pon formula accuracy, not guesswork.

Dis experience become Colin entry into cannabis beyond just getting high. It become mission fi create real solutions dat help alleviate pain en suffering, not just fi pets but fi people. Bentley story is wi foundation, driving wi commitment to quality, innovation, en compassionate care.

Colin Personal Journey — From PTSD to Recovery

Colin also know pharmaceutical dependence personally. Him struggle wid PTSD en benzodiazepine addiction. When him decide fi break free from Xanax, him do it cold turkey — notoriously difficult en dangerous — using cannabinoid knowledge develop keeping Bentley alive.

Di Peace Gummies formula become OilWell product create during midnight experiments while fighting through benzo withdrawal. Fi ensure quick relief, wi also offer Peace Gummies inna vape form, which Colin personally use fi manage him insomnia en severe PTSD. Dis not theoretical knowledge. Colin live what RSO patients live: desperation fi relief, failed pharmaceuticals, discovery dat cannabinoids work when pills nuh work.

Over time, therapeutic benefits Colin first discover through Bentley become core a wi work. Wi develop formulas dat doctors use fi Crohn disease, IBS, ulcerative colitis, PTSD, benzo addiction, en insomnia. Wi focus always been making cannabis accessible en effective fi everyone, including vegans, diabetics, en those wid specific health needs.

ABC13 Media Recognition — Houston Go-To Cannabis Authority

Between September 2019 en April 2023, ABC13 Houston (KTRK) — ABC affiliate serving fourth-largest U.S. city — feature Colin en OilWell Cannabis inna seven distinct news segments spanning business, law, medicine, community health, en politics. Five different reporters seek Colin out: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, en KTRK staff.

When ABC13 need fi explain new cannabis product, dem call Colin. When state agency reverse Delta-8 legality overnight, dem call Colin. When sitting president announce marijuana pardons en station need someone who’d personally live wid cannabis conviction fi contextualize it, dem call Colin. When dem want fi tell story a growing industry pon 4/20, it was Colin hemp field en voice dat anchor report.

September 15, 2019 — CBD Business Boom
Dis earliest feature capture Colin foundational philosophy: “I’m not trying fi sell people snake oil. I’m not trying fi sell people hope. But dere enough research out dere dat people just need fi know en try en have di best possible version fi base dem opinions off of fi give it a fair shot as to whether it right or wrong fi dem.”

Dis quote — from 2019, years before wi formulas publish — is seed a everything wi become. It trace back to dis principle: open-source formula publication, evidence-based research documentation, refusal fi mek unsupported claims.

May 24, 2021 — Delta-8 THC “Legal Weed”
Steve Campion investigative feature include iconic exchange:
Campion: “Why would someone want fi smoke dat?”
Colin: “I don’t give a sh** if it wrong fi seh you’ll get high off it. Maybe unnu want fi get high.”

Dis radical honesty pon mainstream television wid expletive preserve by network become one a Colin most memorable media moments. Di piece balance him unapologetic stance wid medical caution from UTHealth specialist en regulatory advocacy from Texans fi Responsible Marijuana Policy.

August 20, 2021 — COVID Vaccine Giveaway
OilWell give weh 1,000 special edition caviar pre-rolls (approximately $35,000 inna product) fi encourage COVID-19 vaccination. Wi coordinate wid city a Houston fi amplify vaccination effort, demonstrating community orientation dat not hypothetical — when public health crisis require action, wi commit real product en real coordination wid city government, wid no political strings attach.

October 19, 2021 — Delta-8 Ban Impact
When Texas DSHS post update classifying Delta-8 as Schedule I overnight, Colin already proactively remove all Delta-8 products from shelves — before enforcement begin, before most a industry even know change happen. Him try fi spread word to other operators unknowingly shipping Schedule I narcotics. Dis willingness fi absorb major revenue loss, act ethically ahead a enforcement, en position company as expert guide fi industry inna crisis rather dan victim a regulation — dat wi character.

October 7, 2022 — Biden Marijuana Pardon
Dis feature reveal Colin previously face charges fi marijuana possession. Dat personal history transform entire media record. Every feature, every quote bout therapy, education, not selling snake oil — all carry additional weight when unnu understand person saying it have personally experience consequences a cannabis criminalization.

Fi Jamaican readers, dis especially powerful. Cannabis criminalization devastate Jamaican communities fi decades. Colin nuh outside entrepreneur who see business opportunity. He is someone who live consequences en build legal business fi prove industry could operate wid integrity, transparency, en community benefit.

April 21, 2023 — Texas Marijuana Laws 4/20
Most recent feature position OilWell at frontier. Colin “Renaissance” framing reframe present as opportunity rather dan waiting. Nico Richardson comparison (Texas 10,000 active medical cannabis patients vs. Florida 700,000 wid two-thirds di population) demonstrate untapped demand dat apply to many markets, including Jamaica potential patient population.

From September 2019 CBD business profile through Delta-8 boom en bust, COVID community initiative, personal revelation a cannabis conviction, to “Renaissance” framing — Colin media trajectory mirror trajectory a legal cannabis itself.

Wi Philosophy — Four Core Principles

Wi RSO not traditional Rick Simpson Oil. It formulated, multi-cannabinoid product inform by RSO tradition but departing from it inna deliberate, evidence-motivated ways design fi solve problems dat limited Simpson original vision.

1. Accessibility over gatekeeping
No medical card required. Anyone age 21+ can purchase. Wi ship nationwide across United States en internationally to customers who verify local legality. Simpson believe medicine should be accessible to everyone; wi build product en distribution model dat mek dat accessible legally fi Jamaican residents en diaspora communities worldwide.

2. Patient-controlled potency
THCa sell inna acidic, non-psychoactive form. Unnu decide whether fi use raw fi non-psychoactive benefits or decarboxylate into delta-9 THC fi full psychoactive potency. Simpson believe patients should control dem medicine; wi engineer product dat put dat control inna unnu hands through chemistry rather dan rhetoric.

3. Open-source formulas
Wi publish complete formulas publicly — every cannabinoid, every milligram, every percentage — so anyone who cyan afford product can source ingredients en mek dem own version. Simpson give him oil weh free en teach people fi mek it; wi adapt dat ethos fi modern cannabinoid marketplace by selling professionally manufactured product en publishing recipe.

4. Evidence-informed, not evidence-overstating
Wi GENERAL KNOWLEDGE section represent wi commitment to honest education bout what science actually seh. Simpson operate without access to peer-reviewed literature or clinical trial data; wi have dat access en use it fi distinguish what well-support, what emerging, en what overstated.

Farm Bill Compliance en THCa Legal Framework

Di 2018 Farm Bill legalize hemp en hemp-derived products containing less dan 0.3% delta-9 THC by dry weight at federal level inna United States. Dis legal framework foundation a wi RSO product design.

Wi RSO Sublingual Oil contain only 90mg delta-9 THC inna entire 30mL bottle — 3mg per mL — well under 0.3% threshold. All cannabinoids hemp-derived. Product legal under federal law en inna most states.

THCa — Di Game-Changer
THCa acidic, non-psychoactive precursor to delta-9 THC. It not itself delta-9 THC. Dis distinction legally significant: THCa Farm Bill compliant at point of sale because it nuh convert to delta-9 THC yet.

Practical significance substantial. Unnu can decarboxylate THCa into delta-9 THC at home by heating oil at 260°F (125°C) fi 45-60 minutes inna oven-safe glass container. Dis convert 1,500mg THCa into approximately 1,315mg delta-9 THC. Combined wid existing 90mg delta-9 THC inna formula, dis produce approximately 1,405mg total delta-9 THC — giving product psychoactive potency comparable to traditional illegal RSO, entirely at unnu discretion after purchase.

Dis mean same product can function as non-psychoactive anti-inflammatory (use raw) or full-potency psychoactive cannabinoid product (after home decarboxylation). Unnu control di decision. Product legal everywhere all component cannabinoids legal, enabling international shipping to Jamaica en other jurisdictions where hemp-derived products wid less dan 0.3% delta-9 THC permitted.

Important Legal Notice: THCa convert to delta-9 THC when heated. Customers responsible fi understanding en complying wid local laws regarding cannabinoid products. Wi ship wid full documentation, Certificates of Analysis, en receipts. International customers accept all customs en legal responsibility.

Open-Source Formulas — Why Wi Publish Everything

Wi publish complete RSO formulas publicly — every cannabinoid, every milligram amount, every percentage — inna documents including dis one. Di RSO Sublingual Oil en RSO Vape Cartridge formulas detail fully inna dem respective sections.

Rationale straightforward: if someone cyan afford wi products — $129.99 fi sublingual oil, $49.99 fi vape cartridge — dem can see exactly what formula contain, source individual cannabinoid distillates en isolates, en mek dem own version. Di formulas inna dis document ARE di open-source formulas.

Dis direct echo a Rick Simpson original ethos. Simpson give him oil weh free en teach people fi mek it. Him never patent him method, never charge patients. Wi adapt dat ethos fi modern marketplace: sell professionally manufactured, lab-tested, standardized product fi those who want it, en publish complete recipe fi those who want fi mek it demself.

As Colin seh pon ABC13 inna 2019: “I’m not trying fi sell people snake oil. I’m not trying fi sell people hope. But dere enough research out dere dat people just need fi know en try en have di best possible version fi base dem opinions off of fi give it a fair shot as to whether it right or wrong fi dem.”

CBD Golden Paste Recipe — Wi Original Open-Source Formula

Di open-source philosophy nuh start wid RSO — it start wid Bentley. Pon wi About Us page, wi publish di actual CBD golden paste recipe dat save Bentley life, so any pet owner facing similar crisis can mek it demself:

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1-2 teaspoons freshly ground black pepper (important fi absorption)
• CBD oil (dosage depend pon pet size en needs; consult veterinarian)

Instructions:

1. Mix turmeric en water inna saucepan over low heat, stirring continuously until thick paste form (7-10 minutes). Add more water if too thick.
2. Add coconut oil en freshly ground black pepper, stir until thoroughly mixed.
3. Allow fi cool, transfer to jar wid lid, refrigerate up to two weeks.
4. Add small amount a CBD oil to paste before giving to pet, adjusting dosage based pon weight en health needs. Start low en gradually increase.

Serving suggestion: Mix small amount a golden paste wid pet food once or twice daily. Monitor pet fi changes en consult veterinarian if concerns arise. Always consult veterinarian before starting new supplement regimen.

Dis recipe — publish free, years before RSO formulas open-sourced — demonstrate pattern consistent. Wi give weh formula dat save Bentley before wi give weh formula design fi people. Open-source ethos not marketing strategy; it foundational behavior a wi company.

Di Decarboxylation Choice — Patient-Controlled Potency

Traditional RSO always fully decarboxylated. Heat a solvent evaporation convert all THCa into delta-9 THC, leaving patient wid no choice bout psychoactivity — oil always psychoactive.

Wi sublingual formula contain 1,500mg THCa inna acidic, non-psychoactive form. Dis create three distinct usage options:

Option 1 — Raw, no heat: All 1,500mg stay as THCa — completely non-psychoactive. THCa evidence describe potential anti-inflammatory activity via COX-2 inhibition en neuroprotective potential via PPARγ agonism. Dis option compatible wid work, driving, en daytime use wid zero psychoactive impairment.

Option 2 — Fully activated, home decarboxylation: Heat oil at 260°F (125°C) fi 45-60 minutes inna oven-safe glass container. Convert 1,500mg THCa to approximately 1,315mg delta-9 THC. Combined wid existing 90mg delta-9 THC, yield ~1,405mg total delta-9 THC. Combined wid 6,000mg delta-8 THC, activated product achieve psychoactive potency comparable to traditional illegal RSO — 100% legally, because decarboxylation occur at unnu discretion after purchase. Unnu may also transfer controlled portion from original bottle to second oven-safe container, decarboxylating only what unnu intend fi use en preserving remainder inna raw THCa form.

Option 3 — Vape, auto-decarboxylation: Wi RSO Vape Cartridge vaporize at 400-450°F, instantly converting THCa to delta-9 THC wid each inhalation. Every puff deliver freshly decarboxylated cannabinoids. Dis fastest-onset RSO delivery method available.

Conversion chemistry: THCa molecular weight a 358.47 g/mol. Conversion ratio approximately 1mg THCa = 0.877mg delta-9 THC after decarboxylation, reflecting loss a CO₂ molecule during reaction.

Dis design put potency decision entirely inna unnu hands — aligning wid Simpson principle dat patients should control dem medicine, but implementing it through actual product chemistry rather dan one-size-fits-all approach.

Solvent-Free Production

Wi RSO not traditional extraction product. It formulated blend a individual cannabinoid distillates en isolates combine at specific ratios inna controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents present inna finished product.

Dis approach eliminate residual solvent risk — one a most significant safety concerns wid traditional RSO production. Product use organic MCT oil (medium-chain triglycerides) as carrier base. MCT oil is food-grade lipid carrier facilitating cannabinoid absorption through sublingual tissue en providing neutral taste profile — significant improvement over tar-like consistency en solvent-residual odor a traditional RSO.

Third-party lab testing cover cannabinoid potency, terpene profile, en safety panels including pesticides, heavy metals, residual solvents, en microbial contaminants. Certificates of Analysis (COAs) available pon request en accessible through wi website.

Wi Complete Product Portfolio

Beyond RSO, wi produce range a cannabinoid products, each develop from formulation knowledge Colin build over Bentley ten-year journey en him own PTSD/benzo withdrawal experience.

Asshole Peach — Wi most popular product. Carefully formulate experience design fi provide euphoric, long-lasting sensation. Particularly favored by veterans fi ability fi relieve pain en PTSD symptoms without being overly aggressive.

Peace Gummies — Develop directly from Colin own experience wid PTSD en benzodiazepine addiction. Peace Gummies help him quit Xanax cold turkey. Formula also available inna vape form fi quick relief — Colin personally use vape fi manage him insomnia en severe PTSD ongoing.

Custom Creations — Wi offer custom-made products tailored to specific customer needs. Whether specific cannabinoid ratios, particular delivery formats, or formulations fi unique health circumstances, wi design targeted products pon request. Dis include formulations fi vegans, diabetics, en those wid specific dietary or health needs.

Wi Two RSO Product Formats

RSO Sublingual Oil — $129.99

• 30mL bottle (1 fl oz)
• 16,590mg total cannabinoids (553mg per mL)
• Seven cannabinoids: CBD 4,500mg, CBG 3,000mg, delta-8 THC 6,000mg, THCa 1,500mg, delta-9 THC 90mg, CBN 750mg, CBC 750mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper fi precise dosing inna 0.1mL increments
• Onset: 15-45 minutes (sublingual absorption through oral mucosa)
• Peak effects: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19% (sublingual route partially bypass first-pass liver metabolism)
• Approximately 40-60 doses per bottle depending pon serving size

RSO Vape Cartridge — $49.99

• 1-gram cartridge
• 900mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1-2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35% (variable, dependent pon inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400-450°F)

Complete RSO Guide — Wi full product guide wid science, competitive analysis, protocols, en ordering information.

When Fi Use Each Format

Use Case	Recommended Format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability en discretion	Vape	Compact, no measuring required
Precise dosing control	Sublingual	Graduated dropper inna 0.1mL increments
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stay inactive, zero impairment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

Competitive Comparison — OilWell RSO vs. Alternatives

OilWell RSO vs. Texas TCUP Dispensary RSO (e.g., Texas Original)

Dimension	TCUP Dispensary RSO	OilWell RSO
Cannabinoid profile	THC-only (~420mg THC per 0.5g syringe)	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG content	0mg	3,000mg
CBN content	0mg	750mg
CBC content	0mg	750mg
Patient-controlled potency	No — always fully psychoactive	Yes — THCa non-psychoactive until heated by customer
Access requirements	TCUP medical card wid qualifying condition	Age 21+ only, no medical card required
Qualifying conditions	Cancer, PTSD, epilepsy, autism, terminal illness, ALS, MS, seizure disorders, incurable neurodegenerative diseases	None required
Delivery	Must travel to physical dispensary location	Same-day delivery Houston, nationwide en international shipping to Jamaica
Farm Bill compliant	No — state medical cannabis program	Yes — less dan 0.3% delta-9 THC

OilWell RSO vs. Hemp CBD RSO (e.g., Lazarus Naturals)

Dimension	Lazarus Naturals RSO (10mL, 1,000mg)	OilWell RSO (30mL, 16,590mg)
Total cannabinoids	1,000mg	16,590mg
CBD content	~950mg	4,500mg
CBG content	15.5mg	3,000mg
CBN content	0.7mg	750mg
Delta-8 THC	0mg	6,000mg
THCa (convertible to delta-9 THC)	Minimal	1,500mg (convert to ~1,315mg delta-9 THC)
Psychoactive option	No meaningful psychoactive effect	Yes — via THCa decarboxylation en delta-8 THC
Approximate price	$40-50	$129.99

OilWell RSO vs. Traditional Illegal RSO — See Traditional RSO vs. Modern Formulated RSO table inna previous section.

Condition-Specific Usage Context fi Jamaican Patients

Important Disclaimer: Following usage contexts inform by cannabinoid research cite inna GENERAL KNOWLEDGE section en wi formulation rationale. Dem not medical prescriptions, not FDA-approved treatment protocols, not substitute fi professional medical care. Dese products nuh evaluate by Food en Drug Administration en not intended fi diagnose, treat, cure, or prevent any disease. Always consult qualified healthcare provider before using cannabinoid products, especially if unnu have medical condition, taking medications, pregnant or nursing, or have health concerns. Nuh operate vehicles or machinery while under influence a psychoactive cannabinoids.

Fi Jamaican cancer patients undergoing chemotherapy:

• Pre-chemo: 0.5-1.0mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs fi immediate relief (1-2 minute onset)
• Post-chemo: 0.5mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0-2.0mL sublingual before bed (deliver 25-50mg CBN)
• Evidence context: delta-8 THC antiemetic evidence, delta-9 THC nausea/vomiting evidence, CBD anxiolytic buffering

Fi Jamaican chronic pain sufferers (fibromyalgia, arthritis, neuropathy, post-injury pain):

• Daytime: 0.3-0.5mL raw sublingual — provide anti-inflammatory cannabinoid exposure without psychoactive impairment, allowing unnu fi work, drive, care fi family
• Nighttime: 0.5-1.0mL decarboxylated sublingual — combine pain relief wid CBN sleep support
• Breakthrough pain: Vape as needed fi rapid onset
• Evidence context: CBD pain evidence, delta-9 THC pain evidence, beta-caryophyllene CB2 agonism, THCa COX-2 inhibition

Fi Jamaican patients wid sleep disorders (insomnia, disrupted sleep from chronic pain or PTSD):

• Before bed: 1.0-2.0mL sublingual
• At 2.0mL, dis deliver 50mg CBN — dosage level investigate inna 2024 sleep literature
• At 1.0mL, dis deliver 25mg CBN — above 20mg threshold associate wid reduced sleep disturbance inna publish research
• Evidence context: CBN sleep evidence, cannabis en sleep review literature

Fi Jamaican anxiety en stress sufferers:

• Daytime functional relief: 0.3mL raw sublingual — CBD en CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0mL sublingual — full cannabinoid profile including CBN fi sleep architecture
• Evidence context: CBD anxiety evidence, CBG pharmacology, limonene entourage-effect evidence

General titration principle fi all Jamaican users: Start low, go slow. Begin wid 0.25-0.5mL sublingual en assess effects over 2-3 hours before increasing. Individual responses vary based pon body weight, metabolism, tolerance, concurrent medications, en other factors.

Delivery en Global Accessibility to Jamaica

Wi operate di only same-day RSO delivery system inna Houston. Beyond Houston, wi ship nationwide en internationally, including to Jamaica.

Fi Jamaican customers inna Houston area:
If unnu part a Jamaican diaspora community inna Houston, wi offer same-day delivery:

• Texas Medical Center (FREE delivery) — all 60+ TMC institutions including MD Anderson, Memorial Hermann, Methodist, Texas Children, St. Luke
• Inner Loop (610) — Downtown, Midtown, Montrose, Heights, Rice Village, Museum District, River Oaks, Upper Kirby, Galleria ($5)
• Within Beltway 8 — Bellaire, Memorial, Spring Branch, South Houston, Pasadena, Hobby Airport area ($10)
• Greater Houston suburbs — Katy, Sugar Land, Pearland, Clear Lake, Woodlands, Cypress, Tomball, Humble, Kingwood ($15)
• Extended region (60 miles) — Galveston, Baytown, Rosenberg, Conroe, La Porte, Seabrook ($20-25)

Free delivery to Texas Medical Center — world largest medical complex wid over 10 million patient visits annually — reflect wi commitment to accessibility fi patients who need it most, including Jamaican families seeking treatment at world-renowned cancer centers.

Fi Jamaican customers inna United States:
Wi ship to all 50 states where Farm Bill-compliant products legal:

• USPS Priority Mail (2-3 business days)
• FedEx en UPS Ground (3-5 business days)
• Discreet packaging wid no cannabis branding visible
• Tracking provide fi all orders
• Temperature-stable packaging fi summer shipments
• Signature-required option available

Fi Jamaican customers inna Jamaica en worldwide:
Wi ship internationally en deliver to multiple countries across multiple continents. THCa legal framework mek dis possible: because product contain less dan 0.3% delta-9 THC at point of sale, it meet definition a hemp-derived product under 2018 Farm Bill en shippable to jurisdictions wid compatible hemp laws.

Fi Jamaican customers: All international packages include full documentation, Certificates of Analysis (COAs), en receipts fi customs purposes. Minimum flat-fee shipping apply; excessive international shipping costs bill to customer. Customer responsible fi verifying legality inna dem jurisdiction en accept all customs en legal risk.

Contact fi Jamaican orders: (832) 416-2816 or [email protected]

Di significance fi Jamaica: Rick Simpson couldn’t ship him oil anywhere — it was Schedule I, illegal fi produce, possess, or transport. A cancer patient inna Kingston, a chronic pain sufferer inna Montego Bay, a veteran wid PTSD inna Spanish Town, or a ganja advocate inna Negril can now potentially access same clinical-strength multi-cannabinoid RSO formula dat Houston resident receive via same-day delivery. Wi build product dat can move cross borders legally — completing piece a Simpson vision dat prohibition mek impossible during him lifetime.

Wi PANDEM1C SEO technology — proprietary system wid 14 million distinct geopolitical locations inna database en over 300 AI models — drive organic search visibility across six continents, making wi products discoverable to Jamaican patients searching fi RSO inna English, Jamaican Patois search terms, en other languages.

GENERAL KNOWLEDGE — Di Evidence Behind Every Compound

Research Method en Evidence Weighting

Wi prioritize sources inna dis order: human clinical evidence, systematic reviews en meta-analyses, NIH en institutional summaries, den mechanistic or preclinical literature when human data sparse. Dis weighting matter because evidence base nuh evenly distributed. Of compounds inna wi formula, CBD en delta-9 THC have strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, en most terpenes still more dependent pon reviews, animal work, en in vitro pharmacology.

Institutional Baseline from NIH en NCCIH

National Center fi Complementary en Integrative Health state strongest establish cannabinoid evidence is fi:

• Certain rare epilepsies
• Chemotherapy-related nausea en vomiting
• Appetite en weight-loss indications associate wid HIV/AIDS

NCCIH note only modest evidence fi chronic pain en multiple-sclerosis-related symptoms, wid many other claim uses still early-stage research.

Critical safety concerns highlight by NIH:

• Impairment en motor vehicle crash risk
• Cannabis use disorder
• Pregnancy-related concerns
• Contamination or labeling inaccuracy
• THC-vape lung-injury concerns

NCCIH warn dat over-the-counter CBD products may differ from labels en CBD itself associate wid decreased alertness, gastrointestinal effects, liver-related adverse effects, en drug interactions.

Cannabinoid Evidence Profiles

CBD — Most Evidence-Developed Nonintoxicating Cannabinoid

• Best support: Purified CBD have strongest human evidence inna seizure disorders — clearest major-example indication acknowledge by institutional en peer-reviewed literature
• Anxiety: 2024 systematic review en meta-analysis covering 316 participants across eight eligible articles report statistically significant anxiolytic signal, but authors stress clinical sample remain limited en more trials needed before broad conclusions justified
• Pain: 2024 systematic review a clinical en preclinical CBD monotherapy studies conclude pain literature promising but heterogeneous, wid trial quality en consistency still limiting confidence inna broad analgesic claims
• Sleep: 2023 insomnia review find literature remain methodologically weak, wid many studies relying pon nonvalidated subjective measures en relatively few objective sleep assessments
• Safety: 2023 systematic review en meta-analysis find real signal fi liver enzyme elevation en possible drug-induced liver injury inna some CBD contexts, especially relevant fi concentrated oral products en polypharmacy settings

Fi Jamaican patients: CBD di cannabinoid wi can discuss wid most confidence fi seizure disorders. Fi anxiety, pain, en sleep, evidence promising but require cautious interpretation. If unnu managing multiple medications (common among Jamaican elders en chronic disease patients), CBD drug interaction potential require medical supervision.

CBG — Promising Minor Cannabinoid, Limited Clinical Validation

• Evidence profile: Mostly review-level en preclinical; human evidence remain sparse
• Pharmacology: CBG biosynthetic precursor to several major cannabinoids wid pharmacologically distinct profile spanning cannabinoid receptors, alpha-2 adrenoceptors, en 5-HT1A-related signaling
• Potential research areas: Neurologic disorders, inflammatory bowel disease, antibacterial activity — primarily pharmacology-led hypotheses or preclinical findings rather dan mature human therapeutic conclusions
• Caution: CBG already being sell commercially while evidence base remain thin, meaning claims frequently outrun science

Fi Jamaican IBS/ulcerative colitis patients: CBG preclinical gut anti-inflammatory signals interesting but not yet prove inna humans. Wi include 3,000mg inna wi formula because a dis promise, not because a proven efficacy.

Delta-8 THC — Pharmacologically Relevant but Less Clinically Characterized

• Evidence profile: Pharmacologically relevant, psychoactive, much less clinically characterize dan delta-9 THC
• Comparative pharmacology: 2022 review conclude delta-8 THC en delta-9 THC have broadly similar pharmacokinetic en pharmacodynamic behavior. Delta-8 THC partial CB1 agonist wid cannabimimetic activity inna animals en humans, but appear less potent dan delta-9 THC, likely due to weaker CB1 affinity
• Public health: 2023 scoping review find delta-8 evidence base dominate by animal studies, product chemistry, use reports, en public-health concerns rather dan strong modern human trials. Review note reports a adverse consequences en emphasize regulatory en product-quality concerns
• Manufacturing: Recent chemistry en pharmacology review reinforce commercial delta-8 interest tie to greater stability en easier synthesis relative to naturally scarce plant levels, weh why product-byproduct en lab-testing questions matter

Fi Jamaican users: Delta-8 THC should be treat as psychoactive THC analogue wid real pharmacologic activity, incomplete human safety characterization, en more manufacturing-quality uncertainty dan many realize. Di 6,000mg inna wi formula substantial — wi include it fi therapeutic reasons, not just as filler.

THCa — Important Chemically, Limited Direct Human Evidence

• What it is: Acidic precursor a THC, may represent very large share a THC-related content inna raw plant material
• Key formulation issue: THCa decarboxylate into THC during heating en can change over time during storage en processing
• Psychoactivity: Major review stress THCa itself nuh produce psychoactive effects associate wid THC inna humans, but distinction only hold if molecule stay inna acidic form en nuh substantially decarboxylated
• Research status: In vitro en rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, en antineoplastic possibilities, but not equivalent to establish human outcomes

Fi Jamaican users: THCa best understand as highly relevant precursor molecule whose interpretation depend heavily pon route, temperature, processing, en storage. Wi formula 1,500mg give unnu flexibility fi use non-psychoactively or convert to THC at home.

Delta-9 THC — Strongest Human Evidence a Psychoactive Cannabinoids, But Clearest Adverse-Effect Burden

• Institutionally best support: NCCIH identify THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea/vomiting, appetite/weight loss inna HIV/AIDS, en some multiple-sclerosis- en pain-related outcomes, while stressing many other uses remain uncertain or early-stage
• Pain evidence: 2022 systematic review a cannabis-based products fi chronic pain find products wid high THC content or comparable THC:CBD ratios may provide short-term pain benefit, but also increase dizziness, sedation, nausea, en treatment discontinuation due to adverse events
• Pharmacokinetics: Inhaled THC produce effects within seconds to minutes, peak ~15-30 minutes, taper over few hours; oral THC have later onset, later peak, longer duration, weh matter fi both benefit en overconsumption risk
• Mental health risk: 2025 systematic review a high-concentration THC products find consistent unfavorable associations wid psychosis or schizophrenia outcomes en cannabis use disorder, wid concerning signals fi anxiety en depression inna nontherapeutic settings
• Broader safety: Anxiety or panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, vape-related lung-injury concerns

Fi Jamaican patients: Delta-9 THC have legitimate therapeutic relevance inna some settings, but also carry clearest intoxication, psychiatric, en dose-related safety liabilities. Wi formula contain only 90mg total delta-9 THC (3mg/mL) — dramatically lower dan Simpson protocol delivering 600-900mg daily. Dis intentional harm-reduction design.

CBN — Reputation Stronger Dan Evidence

• What marketed fi: Sleep en sedation. Dat reputation widespread, but clinical support far thinner dan market suggest
• Best direct review: 2021 narrative review pon CBN en sleep screen 99 human-study abstracts, review eight full-text articles, find no clinical trials using validated sleep questionnaires or formal polysomnography dat could substantiate strong sleep-promoting claims
• Broader sleep literature: 2024 updated review pon cannabis en sleep conclude overall cannabinoid sleep research still don’t match scale a real-world use, en need fi better-designed, adequately powered trials remain substantial
• Chemical context: Downstream cannabinoid degradation pathways matter; THC can further degrade toward CBN under certain conditions, weh help explain why CBN often discuss inna aging or oxidize cannabis chemistry contexts

Fi Jamaican insomniacs: CBN clearest example where cultural reputation outpace clinical evidence. Wi include 750mg because a promising preclinical work en patient interest, not because a proven efficacy. Wi formula 25-50mg CBN at typical doses align wid dosages being investigate inna emerging research.

CBC — Emerging, Intriguing, Overwhelmingly Preclinical

• Pharmacology: 2024 focused review argue CBC have distinct pharmacodynamics, pharmacokinetics, en receptor behavior relative to better-known cannabinoids, highlighting antinociceptive, antibacterial, en anti-seizure areas as especially interesting research targets
• Older literature: Anti-inflammatory effects, reduce gut hypermobility, modest rodent analgesic activity, possible neurobiological or antiproliferative relevance — but not yet strong evidence fi patient-facing claims
• Safety caveat: 2024 CBC review explicitly note over-the-counter CBC products already being sell despite likkle evidence establishing clinical efficacy or safety

Fi Jamaican research-aware patients: CBC belong inna category a scientifically credible minor cannabinoids deserving more research, not already-validated clinical actives. Wi 750mg inclusion forward-looking, not backward-proven.

Terpene Evidence Profiles

Important framing fi Jamaican users: Terpene claims need even stricter interpretation dan cannabinoid claims. Much literature come from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather dan controlled human studies a cannabis formulations. 2024 entourage-effect review mek dis especially important: terpene bioactivity plausible en sometimes compelling, but robust proof a clinically meaningful entourage effects inna humans remain limited.

Limonene — Multifunctional But Not Cannabis-Specific

• Potential activity: 2021 review describe limonene as multifunctional monoterpene wid antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory possibilities, but overwhelming share a claims come from nonhuman or non-cannabis literature
• Safety note: Limonene oxidation products, especially hydroperoxides, clinically relevant contact allergens important inna patch-testing literature

Fi Jamaican citrus lovers: Limonene biologically active en widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly support inna humans. Di citrus brightness inna wi terpene profile a sensory delight, not proven therapy.

Myrcene — Preclinical Promise, Limited Human Proof

• Research summary: 2021 myrcene review describe anxiolytic, antioxidant, anti-inflammatory, analgesic properties en discuss possible mechanisms, but explicitly state human studies lacking
• Interpretation caution: Myrcene often invoke as if it proven sedating terpene explaining couch-lock or sleep effects. Dis stronger claim dan human evidence currently supports

Fi Jamaican relaxation seekers: Myrcene plausible bioactive terpene, but compound-specific clinical claims bout mood, pain, or sedation remain far ahead a definitive human proof.

Caryophyllene — Di CB2 Agonist Standout

• Why it stand out: 2021 focused review describe beta-caryophyllene as selective CB2 receptor agonist, unusual en especially relevant when discussing cannabis terpenes inna pharmacologic rather dan purely aromatic terms
• Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective actions repeatedly discuss, but human clinical confirmation remain limited

Fi Jamaican inflammation sufferers: Beta-caryophyllene strongest candidate fi terpene wid cannabinoid-system significance, but still should not be describe as clinically proven fi outcomes commonly attribute to it.

Pinene — Brain Health Hypotheses Not Yet Proven

• Brain-health framing: 2021 review pon pinene en linalool as terpene-based medicines fi brain health find antioxidant, anti-inflammatory, neuroprotective signals justifying future study, but emphasize evidence mostly preclinical en well-designed clinical trials lacking
• Interpretation caution: Claims dat pinene reliably improve memory, sharpen attention, or counterbalance THC-related cognitive effects remain interesting hypotheses rather dan settle clinical facts

Linalool — Similar Profile to Pinene

• Research summary: Repeatedly discuss inna relation to stress, mood, brain-health pharmacology. 2021 brain-health review find enough preclinical signal fi justify continued investigation inna neurological en psychiatric contexts, while still emphasizing lack a robust human trials
• Additional literature: Separate review discuss possible antidepressant mechanisms en neuropharmacologic relevance, but remain translational rather dan definitive clinical story
• Safety note: As wid limonene, oxidize linalool hydroperoxides recognized allergens inna dermatitis literature

Humulene — Cannabimimetic Properties But Early

• Scoping-review findings: 2024 scoping review analyze 340 articles en find broad preclinical evidence fi anti-inflammatory en other biologic effects, wid some rodent work even suggest cannabimimetic properties via CB1 en adenosine A2a pathways
• Interpretation caution: Findings valuable fi hypothesis generation, but nuh yet establish consistent human efficacy across pain, inflammation, or mood outcomes

Terpinolene — Least Clinically Characterized

• Systematic-review findings: 2021 terpinolene review screen 2,449 records, include 57 studies, concluding terpinolene have range a reported biological effects but evidence base still dominate by in silico, in vitro, en animal studies rather dan human trials
• Interpretation caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not as establish compound-specific clinical effects

Research Limits en Interpretation Rules

1. Evidence base highly uneven. CBD en delta-9 THC can support most detailed human-facing statements; di rest require more caution.
2. Data categories nuh interchangeable. Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, en terpene-only data nuh interchangeable. One common error a letting evidence from one category stand in fi another.
3. Minor cannabinoids commercially interesting BECAUSE dem underexplored, but dat also mean claims round dem often become inflated.
4. Product quality matter as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, en route-dependent pharmacokinetics all materially affect interpretation inna real-world products.
5. Fi THCa in particular, chemistry a destiny: Storage en heating can change actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC.

Common Overstatements Fi Avoid

Overstatement: CBN clinically proven sleep cannabinoid.
More accurate: Specific sleep evidence fi CBN remain weak en dated, wid no strong validated-trial base yet identify.

Overstatement: Myrcene proven human sedative dat reliably explain couch-lock.
More accurate: Myrcene have plausible preclinical bioactivity, but direct human proof fi dat common claim limited.

Overstatement: Terpenes in general have proven entourage effects inna patients.
More accurate: Entourage hypotheses influential en worth studying, but robust clinical proof remain limited en highly compound-specific.

Overstatement: THCa always nonpsychoactive.
More accurate: THCa itself not THC, but heating en processing can convert THCa into THC, changing effective exposure.

Overstatement: Delta-8 THC safe because it hemp-derived.
More accurate: Delta-8 THC psychoactive, pharmacologically close to delta-9 THC, en often entangle wid manufacturing en testing concerns.

Practical Takeaways Fi Wi Formulas

• Most evidence-developed actives: CBD en delta-9 THC
• Delta-8 THC not trivial or purely mild ingredient; it psychoactive cannabinoid wid less robust safety en efficacy characterization dan delta-9 THC
• THCa meaningfully changes wid processing en should not be interpret same way inna raw, gently handle, en heated formats
• CBG, CBN, CBC scientifically credible but clinically immature compare wid CBD en THC
• Listed terpenes likely highly relevant to aroma, flavor, en potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully en only where directly support

Wi RSO Sublingual Oil Formula

Cannabinoid	Amount (mg)	% of Total
CBD	4,500	27.1%
CBG	3,000	18.1%
Delta-8 THC	6,000	36.2%
THCa	1,500	9.0%
Delta-9 THC	90	0.5%
CBN	750	4.5%
CBC	750	4.5%
Total	16,590	100%

Additional specifications:

• Active cannabinoids per mL: 553mg
• Live terpenes: 5%
• Carrier: Organic MCT oil
• Format: 30mL bottle wid graduated dropper (0.1mL increments)
• Onset: 15-45 minutes
• Duration: 4-6 hours
• Bioavailability: 13-19%
• Doses per bottle: 40-60 depending pon serving size

What dis mean fi Jamaican users: Dis clinical-strength formulation. At 553mg/mL, it one a most concentrated legal cannabinoid products available. Di 16,590mg total mean unnu getting substantial amounts a seven different cannabinoids, each at levels dat match or exceed dosages use inna publish research. Dis nuh diluted CBD oil — dis full-spectrum, research-informed RSO design fi serious therapeutic use.

Wi RSO Vape Cartridge Formula

Cannabinoid	Percentage	Approx. mg per gram
CBD	30%	300mg
CBG	20%	200mg
Delta-8 THC	15%	150mg
THCa	10%	100mg
CBN	10%	100mg
CBC	10%	100mg
Total	95%	~950mg

Additional specifications:

• Live terpenes: 5%+
• Format: 1-gram cartridge
• Thread: 510 universal battery compatibility
• Onset: 1-2 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35%
• Auto-decarboxylation: THCa convert to delta-9 THC at vaping temperature (400-450°F)

What dis mean fi Jamaican users: Dis wi fast-acting format. When unnu need immediate relief from breakthrough pain, panic attack, or acute nausea, di vape deliver cannabinoids to bloodstream within 1-2 minutes. Di auto-decarboxylation mean every puff give unnu freshly activate THC alongside other cannabinoids. Keep dis inna unnu pocket fi emergencies while using sublingual oil fi daily maintenance.

Terpene Profile (Both Products)

• Limonene — Citrus-bright notes
• Myrcene — Earthy foundation
• Caryophyllene (β-caryophyllene) — Pepper/spice character
• Pinene — Forest-fresh aroma
• Linalool — Floral, lavender notes
• Humulene — Earthy, woody undertones
• Terpinolene — Piney, fruity, sparkling finish

Overall sensory experience: Di terpene blend create complex, layered aroma en flavor profile dat evolve as product warm under tongue or inna vape device. Fi Jamaican users familiar wid traditional ganja aromas, unnu recognize some elements while appreciating di refined, non-combustion delivery. Di terpenes nuh just fi smell — dem include at 5% because a plausible bioactivity via entourage effect, even though robust human clinical proof remain limited.

How Wi Formulas Connect to Evidence inna Dis Document

Every cannabinoid inna wi formula — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC — have it own evidence profile inna GENERAL KNOWLEDGE section. Every terpene — limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene — cover wid preclinical en review-level evidence.

Di formulas publish yah anchor to per-compound evidence summaries dat explain what well-support by human clinical data, what emerging from review en preclinical literature, en what overstated relative to current evidence base. Where wi RSO guide page mek specific research claims bout individual cannabinoids or terpenes, dis document provide source evaluation context — same peer-reviewed citations, same evidence-tier assessments, same cautious interpretation framework.

Wi evidence hierarchy, overstatement warnings, en safety notes apply equally to wi own products. Wi nuh exempt wi self from same evidence standards apply to broader cannabinoid field. Dat intentional. Wi position — as state by Colin Valencia inna 2019 — dat people deserve best possible version a information so dem can give it fair shot en decide fi demself whether it right or wrong fi dem.

Fi Jamaican readers: Dis wi promise to unnu — wi hold wi self to same rigorous evidence standards wi apply to everyone else. Inna market where exaggerated claims common, wi giving unnu di actual science, di actual formulas, en di honest assessment a what wi know en don’t know.

Ordering Information fi Jamaican Customers

RSO Sublingual Oil: $129.99 (30mL, 16,590mg total cannabinoids)
RSO Vape Cartridge: $49.99 (1g, ~900mg total cannabinoids)

How fi order from Jamaica:

1. Visit wi website: https://oilwellcbd.com/thca-rick-simpson-oil-rso-by-oilwell-cannabis-of-houston-texas/
2. Verify Jamaican hemp product import laws compatible wid Farm Bill-compliant products
3. Place order en select international shipping
4. Wi provide full COAs, customs documentation, en receipts
5. Accept delivery en verify product integrity

Contact wi:
Phone: (832) 416-2816
Email: [email protected]
Instagram: @oilwellcbd
Address: 810 Richmond Ave, Houston, TX 77006 (Montrose neighborhood)

Business hours (Houston time):
Monday-Thursday: 10:00 AM – 7:00 PM
Friday-Saturday: 10:00 AM – 10:00 PM
Sunday: 10:00 AM – 4:00 PM

Fi Jamaican diaspora inna Houston: Visit wi Montrose location fi see products, talk wid wi team, en experience di same-day delivery service weh mek wi Houston trusted cannabis source.

Final Thoughts Fi Wi Jamaican Community

Rick Simpson story begin wid a man who fail by di medical system en find him own path. Colin Valencia story begin wid a dog who fail by veterinary medicine en find cannabinoid salvation. Dese parallel origins reflect universal truth: when conventional care fall short, cannabis offer hope.

But hope without honesty just hype. Dat why wi publish dis complete document — every formula, every evidence assessment, every safety concern, every limitation a what wi know. Wi believe Jamaican patients, caregivers, en healthcare providers deserve nothing less.

Whether unnu inna Kingston dealing wid chronic pain weh keep unnu from enjoying di beaches, inna Montego Bay managing chemotherapy side effects, inna Spanish Town struggling wid PTSD, or inna rural Jamaica seeking alternatives to expensive pharmaceuticals — wi see unnu. Wi respect unnu need fi honest information. Wi respect unnu right fi mek inform decisions bout unnu health. En wi respect unnu intelligence enough fi give unnu di full picture, not a sales pitch.

Di open-source formulas yah fi anyone who need dem. Di evidence yah fi anyone who want evaluate it. Di products yah fi anyone who choose fi purchase dem. En wi team yah fi anyone who have questions.

Wi OilWell Cannabis. Wi Houston-based. Wi evidence-grounded. En wi yah fi Jamaica.

ENGLISH

Rick Simpson Oil (RSO) in Jamaica: The Complete Guide by OilWell Cannabis

Understanding Rick Simpson Oil Through a Jamaican Lens

Who is Rick Simpson?

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada — a working-class tradesman, not a doctor or scientist. His story resonates deeply with what we see across Jamaica: ordinary people seeking healing when conventional medicine falls short. In 1997, while working at a hospital in Moncton, Simpson suffered a serious head injury from a scaffolding fall. The aftermath left him with persistent tinnitus, dizziness, and post-concussion symptoms that doctors couldn’t resolve. The medications they prescribed either failed to help or made his condition worse. When cannabis provided more relief than anything his physicians offered, his doctor refused to support it. Sound familiar? Many Jamaicans know this pattern all too well — the system failing, and having to find your own way forward.

Simpson’s interest in concentrated cannabis oil deepened after learning about a 1974 NIH-funded study at the Medical College of Virginia, where THC reportedly slowed tumors in mice. That study — intended to demonstrate harm — became a foundational reference for Simpson, even though its findings were never replicated in controlled human cancer trials. This is the same kind of early research that sparked curiosity throughout Jamaica’s ganja culture for decades.

The pivotal moment came in 2003. Simpson reported that three bumps on his arm were diagnosed as basal cell carcinoma. Rather than pursuing conventional treatment, he applied concentrated cannabis oil directly to the lesions, covered them with bandages, and claimed they disappeared within four days. No independent medical verification has ever been published. No biopsy confirmation. No clinical follow-up in any peer-reviewed source. Yet this personal experience became the origin story of Rick Simpson Oil.

Important context for our Jamaican community: Simpson’s account is personal testimony, not medical evidence. The absence of clinical documentation means these events cannot be evaluated as scientific proof. But they are historically significant as the catalyst for a global movement — one that reached Jamaica’s shores long before legalization talks began here. We respect Simpson’s story while committing to the evidence standards Jamaicans deserve.

The Crusade — Spreading the Oil

After his 2003 experience, Simpson committed himself to producing and distributing concentrated cannabis oil from his property in Maccan, Nova Scotia. He gave it away for free to cancer patients and others in his community. He charged nothing. By his account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and more.

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, which became one of the most widely shared cannabis advocacy films of its era. Within cannabis communities worldwide — including Jamaica’s deep-rooted ganja culture — it was foundational. For many, Run From The Cure was their first introduction to concentrated cannabis oil as medicine.

Simpson’s advocacy brought him into direct conflict with Canadian law. The RCMP raided his property in 2005 and again in 2009. He was charged with cultivation, possession, and trafficking. Facing continued legal pressure, Simpson eventually left Canada for Europe, continuing his advocacy from abroad. This pattern of criminalization mirrors what ganja farmers and healers faced in Jamaica for generations — punished for a plant the world was only beginning to understand.

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story and maintained phoenixtears.ca as his advocacy platform. He remained consistent and uncompromising: cannabis oil could cure cancer, and pharmaceutical companies, governments, and medical institutions were suppressing this knowledge.

Important context for Jamaican readers: Simpson’s conspiratorial framing reflects a worldview shared by many in the early cannabis movement. We present it here not to endorse or dismiss it, but to understand why RSO became culturally significant. Jamaica’s own history with cannabis prohibition and spiritual suppression gives us unique insight into this distrust of institutions. The evidence-based assessment of his medical claims follows below — because you deserve honesty, not hype.

The Traditional RSO Protocol — Simpson’s 60-Gram, 90-Day Regimen

Simpson’s core recommendation was structured oral protocol: consume 60 grams of concentrated cannabis oil over approximately 90 days. He described this as a cancer treatment protocol, though he recommended it for numerous conditions. Here’s the detailed breakdown:

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over roughly 90 days. Simpson considered this the minimum for serious cancer treatment.

Titration Schedule

• Week 1: Begin with a dose the size of half a grain of dry rice — about 10-15 mg of oil — three times daily. Total daily intake: 30-45 mg. The goal is to let the body adjust to THC’s psychoactive effects.
• Weeks 2-5: Double the dose every four days. By week five, reach approximately 1 gram (1,000 mg) of oil per day, divided into three doses.
• Weeks 5-12: Maintain 1 gram per day, divided into three 333 mg doses, until all 60 grams are consumed.

Administration Methods

• Primary — oral: Place under tongue or swallow. Simpson considered this the most important route for systemic absorption and internal cancers.
• Secondary — topical: For skin cancers, apply directly to lesions, cover with bandage, change every 3-4 days. Combined with oral dosing.
• Not recommended as primary — inhalation: Simpson acknowledged smoking or vaporizing for immediate symptom relief (pain, nausea) but maintained oral route was necessary for sustained, high-dose exposure.

Tolerance and Psychoactive Effects

• Simpson claimed patients develop THC tolerance within 3-4 weeks.
• He considered euphoria, sedation, or disorientation minor and temporary side effects.
• Recommended initial doses at night to sleep through early psychoactive effects.
• Warned against driving or operating machinery during titration.

Post-Protocol Maintenance

After completing 60 grams, Simpson recommended 1-2 grams per month indefinitely for long-term health and cancer prevention.

Dietary and Lifestyle Recommendations

Simpson advocated reducing sugar, avoiding processed foods, and improving nutrition — though his dietary advice was secondary and general compared to his detailed oil protocol.

Important Context for Jamaican Patients
This protocol was designed by one person based on personal experience. It was not developed through clinical trials, dose-finding studies, or formal research. Critical points:

• No controlled trial validation. No published randomized controlled trials, cohort studies, or well-documented case series evaluate this specific 60-gram/90-day protocol for any cancer type or condition.
• Assumes crude, unstandardized material. The 60-gram quantity assumes single-strain, THC-dominant extract with no standardized potency. Actual THC content varied wildly.
• Very high THC exposure. At peak dosing, patients consumed roughly 1 gram of high-THC oil daily. Assuming 60-90% THC, that’s 600-900 mg of delta-9 THC per day — far exceeding anything studied clinically. The FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5-20 mg per day.
• Real risks at these doses. Consuming 600-900 mg THC daily carries serious risks: severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder. These are well-documented in the research we’ll discuss later.
• Oncology context. Patients with active cancer are medically complex. Using unregulated, unstandardized cannabis oil as primary treatment — potentially in place of proven therapies — introduces harm beyond the oil itself.

What Traditional RSO Was — The Product

Traditional RSO refers to the specific oil Simpson made and advocated for, defined by his method and materials:

Source Material

Simpson used high-THC, indica-dominant cannabis strains. He favored heavy, sedating indica genetics and recommended against sativa for cancer treatment. He grew his own or sourced from trusted growers. There was no strain standardization — material varied by availability and season.

Extraction Solvent

Simpson originally used naphtha (petroleum-based lighter fluid) or 99% isopropyl alcohol. He warned against butane or acetone. Neither naphtha nor isopropyl alcohol is food-grade. Naphtha may contain benzene, toluene, xylene, and other toxic or carcinogenic compounds. Incomplete solvent purging — difficult to verify without lab testing — leaves potentially harmful residues.

Extraction Process

1. Dry cannabis in bucket
2. Cover with solvent, agitate to dissolve cannabinoids
3. Filter solvent through cheesecloth into collection vessel
4. Repeat with fresh solvent
5. Evaporate solvent in rice cooker at low heat
6. Thick, dark oil remains at bottom
7. Transfer to oral syringes for storage and dosing

The rice cooker maintains temperature that evaporates solvent without excessive cannabinoid degradation — but it’s still high enough to decarboxylate THCa into THC and destroy most volatile terpenes.

Appearance and Physical Characteristics

Traditional RSO was extremely dark — nearly black — thick, viscous, tar-like oil with strong cannabis odor and possible solvent-residual smell. Sticky and difficult to handle at room temperature, more fluid when warmed.

Cannabinoid Profile

• Primarily decarboxylated delta-9 THC. Heat converted essentially all THCa to delta-9 THC. Traditional RSO was activated, THC-dominant.
• Naturally occurring minor cannabinoids. Whatever CBD, CBN, CBC, CBG the source strain contained were present at natural ratios — not controlled, measured, or targeted.
• No ratio control. Profile entirely determined by genetics and growing conditions.
• Estimated THC content. Depending on starting material, likely 60-90% total THC by weight — never lab-verified in traditional production.

Terpene Content

Minimal to none. Solvent extraction dissolves terpenes along with cannabinoids, and high-heat evaporation volatilizes terpenes at temperatures well below cannabinoid degradation thresholds. Traditional RSO was effectively stripped of terpene content.

Standardization and Testing

None. Every batch was different. No Certificate of Analysis, no cannabinoid quantification, no contaminant screening. Simpson operated before cannabis legalization and standardized lab-testing infrastructure.

Residual Solvent Risk

This is one of the most significant safety concerns. Naphtha and isopropyl alcohol are not food-grade. Incomplete purging leaves potentially harmful residues. Modern extraction uses food-grade ethanol or supercritical CO₂ specifically to address this.

What This Means for Jamaica
Many products sold as “RSO” in Jamaica today bear little resemblance to what Simpson originally made. The term has become generic. If you’re buying RSO in Kingston, Montego Bay, or from local producers in the Blue Mountains, you need to know: traditional RSO had no standardization, no testing, destroyed terpenes, and carried solvent risks. The modern evolution matters for your safety.

Simpson’s Claims vs. The Evidence

Rick Simpson made expansive therapeutic claims: RSO could cure cancer and was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and more. He was adamant, consistent, and public about these claims throughout his advocacy career.

Let’s evaluate these against actual evidence, using the same standards we apply to our own products.

What Simpson Was Not

Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted results to peer review. His evidence base consisted of personal experience, self-reported patient outcomes, and informal testimonials — with no controls, no independent verification, no imaging confirmation, no long-term follow-up, no blinding.

What The Preclinical Literature Shows

The preclinical cannabinoid-cancer literature does exist and is scientifically interesting:

• In vitro studies demonstrate THC and CBD can induce apoptosis (programmed cell death), inhibit proliferation, and reduce angiogenesis in certain cancer cell lines
• Animal model studies show some tumor-growth inhibition in mice and rats treated with cannabinoids
• These findings generate legitimate scientific interest and ongoing research

What The Preclinical Literature Does NOT Show

• These findings have not translated into proven human cancer cures. The gap between in vitro or animal results and human clinical outcomes is vast, well-documented across all oncology research.
• No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.
• Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been conducted, but they are exploratory, small, and have not produced results supporting cancer-cure claims.

Institutional Positions

• U.S. National Cancer Institute (NCI): Acknowledges cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as cancer treatment.
• U.S. Food and Drug Administration (FDA): Has not approved any cannabis plant product for cancer treatment. The only FDA-approved cannabinoid-related products are for specific indications: Epidiolex (CBD) for certain seizure disorders, and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting.
• Health Canada: Has never approved RSO or cannabis oil as cancer cure.
• NCCIH: Explicitly states strongest cannabinoid evidence is for rare epilepsies, chemo nausea/vomiting, and HIV/AIDS appetite — not cancer cure.

What Simpson Got Right

Simpson drew attention to cannabinoids as a serious biomedical research area when most of the world was ignoring or suppressing that conversation. His advocacy — however scientifically imprecise — helped create the political, cultural, and social conditions for the legal cannabis industry and research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness, and the term RSO remains the most recognized name for full-spectrum cannabis extract.

What He Overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it’s not supported now. Encouraging patients — particularly cancer patients — to rely on RSO as primary treatment in place of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in alternative medicine. Simpson’s absolute certainty about curative claims exceeded what the evidence could support and still exceeds it today.

The Legacy and Evolution

The term RSO is now used broadly and loosely across the legal cannabis industry. Many products labeled RSO bear little resemblance to Simpson’s original method. Simpson himself has been critical of commercial products that use the RSO name while departing from his philosophy — he gave oil away for free and urged people to make their own rather than buy from companies.

This philosophical tension is real. Simpson’s model was anti-commercial, DIY, free-access. The modern industry has commercialized, standardized, and regulated what he distributed freely. Whether that’s improvement (quality control, lab testing, dosing precision) or betrayal (profit extraction, regulatory gatekeeping) depends on perspective. The cannabis community remains divided.

What is not in dispute: modern RSO has evolved substantially. Those changes are directly relevant to what we offer Jamaican patients today.

Traditional RSO vs. Modern Formulated RSO

Dimension	Traditional RSO	OilWell Formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None — every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge
THCa preservation	No — fully decarboxylated by heat	Yes — THCa included as separate ingredient at 1,500mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why Our Formulas Diverge From Traditional RSO

We deliberately depart from traditional RSO in evidence-motivated ways:

Multi-cannabinoid approach: Traditional RSO relied on whatever single strain the maker grew. Our formulas intentionally include seven cannabinoids because entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited.

Terpene preservation and addition: Traditional RSO had essentially no terpenes due to solvent and heat destruction. We include live terpenes at 5% with seven specific terpenes because terpene bioactivity is plausible and supported at preclinical levels.

THCa as separate ingredient: Traditional RSO fully decarboxylated everything. Our sublingual formula includes 1,500mg THCa as distinct ingredient, preserving the acidic precursor because THCa literature suggests potentially relevant non-psychoactive bioactivity lost during conversion.

Reduced delta-9 THC dominance: Traditional RSO was 60-90% delta-9 THC. Our sublingual formula uses only 90mg delta-9 THC while distributing content across CBD (4,500mg), CBG (3,000mg), delta-8 THC (6,000mg), CBN (750mg), and CBC (750mg). This reflects broader cannabinoid research rather than single-compound dominance.

Product format innovation: Simpson envisioned only oral oil from syringe. We offer both 30mL sublingual oil and 1-gram vape cartridge, each with format-specific formulation acknowledging different pharmacokinetic profiles.

Solvent Safety and Extraction Evolution

Traditional RSO used naphtha or isopropyl alcohol — neither food-grade. Naphtha is petroleum-based and may contain benzene, toluene, xylene. Incomplete purging leaves harmful residues.

Modern cannabis extraction uses food-grade ethanol or supercritical CO₂. These allow more complete solvent removal, and finished products can be tested for residual solvents using validated analytical methods like headspace gas chromatography. This is one of the most straightforward improvements the modern regulated industry made over traditional RSO.

The Decarboxylation Question

Traditional RSO was fully decarboxylated. Rice cooker heat (60-80°C for naphtha, ~82°C for isopropyl) converted essentially all THCa to delta-9 THC. This meant acidic cannabinoids in raw cannabis were lost.

Our sublingual formula deliberately preserves 1,500mg THCa as distinct ingredient. This is intentional formulation choice informed by THCa evidence showing potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism — bioactivity lost when THCa converts to THC.

Terpene Loss in Traditional RSO

Terpenes are volatile aromatic compounds with low boiling points (21-157°C). Traditional RSO destroyed terpenes in two ways: dissolving them into solvent wash, then evaporating them during high-heat removal. Whatever aromatic or potentially bioactive terpenes the source cannabis contained were lost.

Our formulas specify live terpenes at 5% with defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each has evidence profile in our GENERAL KNOWLEDGE section. Entourage-effect literature provides theoretical framework for why preserving terpenes alongside cannabinoids may matter pharmacologically.

Evidence Standards Then and Now

Rick Simpson operated in pre-legalization, pre-lab-testing era. When he began in early 2000s, cannabis was illegal in Canada and most of the world. No regulatory framework, no standardized testing, no legal pathway for clinical research, no peer-reviewed journals dedicated to cannabis therapeutics. The underground was the only access point, personal experience the primary evidence currency.

Simpson’s methods reflected those constraints. His evidence was anecdotal, production unstandardized, claims untested in any formal sense. This isn’t necessarily moral failing — it’s description of his environment.

This document takes fundamentally different approach. Our GENERAL KNOWLEDGE section applies formal evidence hierarchy: human clinical evidence first, then systematic reviews, institutional summaries, then preclinical literature. Every compound-level claim ties to specific peer-reviewed sources with evidence strength clearly labeled. We honor RSO’s historical origin while committing to modern cannabinoid science standards. Where Simpson relied on personal testimony, we rely on published literature and institutional sources.

Simpson’s Protocol vs. Modern Dosing

Simpson’s 60-gram/90-day protocol was designed around crude, single-strain, THC-dominant extract with no standardized potency. Direct comparison between his dosing and our modern, standardized, multi-cannabinoid formulation isn’t straightforward — the products are fundamentally different.

Key differences:

• Cannabinoid concentration: Our sublingual formula delivers 553mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios: Simpson’s oil was 60-90% delta-9 THC. Our formula distributes 16,590mg total cannabinoids across CBD (4,500mg), CBG (3,000mg), delta-8 THC (6,000mg), THCa (1,500mg), delta-9 THC (90mg), CBN (750mg), and CBC (750mg) — completely different pharmacologic profile.
• Terpene presence: Simpson’s oil had no terpenes. Our formula includes live terpenes at 5%, which may influence absorption, effect, and tolerability.
• Delta-9 THC exposure: Simpson’s protocol at peak dosing delivered ~600-900mg delta-9 THC per day. Our sublingual formula contains only 90mg delta-9 THC in entire 30mL bottle (3mg per mL), making per-dose exposure dramatically lower.

Our dosing guidance is developed independently of Simpson’s protocol, informed by per-compound evidence in GENERAL KNOWLEDGE section and responsible titration principles accounting for each individual cannabinoid’s safety profile.

About OilWell Cannabis and Our RSO Formula

Our Origin Story

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin grew up in McAllen, Texas — right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. This background shaped Colin’s understanding of suffering, accessibility, and resilience — values that resonate across Jamaica’s own communities facing economic hardship and systemic challenges.

Colin’s childhood was marked by exposure to both opportunities and dangers of border life. Early on, he learned to hustle, taking on risky work transporting items across the border for various groups. Those experiences exposed him to complexities and dangers. Many of his best friends have been killed or are in prison because of associated dangers. He faced every form of violence imaginable, both in streets and across border. By sixteen, he had to leave home for good.

Despite dangers, Colin didn’t fall into darkest paths like selling harder substances. Instead, he focused on cannabis, seeing it as safer and more beneficial alternative. He grew up in traditional cannabis world long before legalization, learning the plant intimately while operating in shadows. Over time, he transitioned from early risky ventures to creating legal, legitimate business in industry he believes in.

Colin later became formally trained software engineer and did custom development work for Baylor College of Medicine, one of most prestigious medical institutions in Texas Medical Center. That combination — deep cannabis plant knowledge plus medical-grade technical precision — defines our approach.

Bentley’s Story — Our True Beginning

Our company’s origin begins with a dog named Bentley. Bentley was more than pet — he was family, companion who stood by Colin through toughest times. When Bentley fell seriously ill, veterinarians delivered verdict no pet owner wants: euthanasia was only humane option. Bentley was paralyzed in back legs. They said pain medications would destroy his internal organs, causing more suffering. Choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley wasn’t option. Colin had already faced too much loss and seen too much suffering. Bentley was fighter, just like him. In desperate search for alternatives, Colin stumbled upon CBD healing properties through question that changed everything.

A kind-hearted rescue worker named Jessica asked: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience — but recreational. He’d never explored therapeutic applications. Jessica’s question exposed blind spot that became mission.

Determined to save Bentley, Colin learned to create CBD golden paste — specialized cannabinoid formula for pets. It wasn’t cure, but it was lifeline and hope. And that hope delivered what veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. This was not placebo effect — dogs don’t respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those ten years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced:

• Neurodegeneration led to understanding CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection
• Dementia led to CBC’s role in neurogenesis
• Glaucoma led to THC’s CB1 agonism for intraocular pressure reduction
• Crippling arthritis led to multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. Pharmaceutical precision mattered — Bentley’s life depended on formula accuracy, not guesswork.

This experience became Colin’s entry into cannabis beyond just getting high. It became mission to create real solutions that help alleviate pain and suffering, not just for pets but for people. Bentley’s story is our foundation, driving our commitment to quality, innovation, and compassionate care.

Colin’s Personal Journey — From PTSD to Recovery

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey — notoriously difficult and dangerous — using cannabinoid knowledge developed keeping Bentley alive.

The Peace Gummies formula became an OilWell product created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, we also offer Peace Gummies in vape form, which Colin personally uses to manage his insomnia and severe PTSD. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, discovery that cannabinoids work when pills do not.

Over time, therapeutic benefits Colin first discovered through Bentley became core of our work. We’ve developed formulas that doctors use for Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. Our focus has always been making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

ABC13 Media Recognition — Houston’s Go-To Cannabis Authority

Between September 2019 and April 2023, ABC13 Houston (KTRK) — ABC affiliate serving fourth-largest U.S. city — featured Colin and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different reporters sought Colin out: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff.

When ABC13 needed to explain new cannabis product, they called Colin. When state agency reversed Delta-8 legality overnight, they called Colin. When sitting president announced marijuana pardons and station needed someone who’d personally lived with cannabis conviction to contextualize it, they called Colin. When they wanted to tell story of growing industry on 4/20, it was Colin’s hemp field and voice that anchored report.

September 15, 2019 — CBD Business Boom
This earliest feature captured Colin’s foundational philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

This quote — from 2019, years before our formulas were published — is seed of everything we became. It traces back to this principle: open-source formula publication, evidence-based research documentation, refusal to make unsupported claims.

May 24, 2021 — Delta-8 THC “Legal Weed”
Steve Campion’s investigative feature included iconic exchange:
Campion: “Why would someone want to smoke that?”
Colin: “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.”

This radical honesty on mainstream television with expletive preserved by network became one of Colin’s most memorable media moments. The piece balanced his unapologetic stance with medical caution from UTHealth specialist and regulatory advocacy from Texans for Responsible Marijuana Policy.

August 20, 2021 — COVID Vaccine Giveaway
OilWell gave away 1,000 special edition caviar pre-rolls (approximately $35,000 in product) to encourage COVID-19 vaccination. We coordinated with city of Houston to amplify vaccination effort, demonstrating community orientation that is not hypothetical — when public health crisis required action, we committed real product and real coordination with city government, with no political strings attached.

October 19, 2021 — Delta-8 Ban Impact
When Texas DSHS posted update classifying Delta-8 as Schedule I overnight, Colin had already proactively removed all Delta-8 products from shelves — before enforcement began, before most of industry even knew change happened. He tried to spread word to other operators unknowingly shipping Schedule I narcotics. This willingness to absorb major revenue loss, act ethically ahead of enforcement, and position company as expert guide for industry in crisis rather than victim of regulation — that’s our character.

October 7, 2022 — Biden Marijuana Pardon
This feature revealed Colin has previously faced charges for marijuana possession. That personal history transforms entire media record. Every feature, every quote about therapy, education, not selling snake oil — all carry additional weight when you understand person saying it has personally experienced consequences of cannabis criminalization.

For Jamaican readers, this is especially powerful. Cannabis criminalization has devastated Jamaican communities for decades. Colin isn’t outside entrepreneur who saw business opportunity. He is someone who lived consequences and built legal business to prove industry could operate with integrity, transparency, and community benefit.

April 21, 2023 — Texas Marijuana Laws 4/20
Most recent feature positioned OilWell at frontier. Colin’s “Renaissance” framing reframed present as opportunity rather than waiting. Nico Richardson’s comparison (Texas 10,000 active medical cannabis patients vs. Florida 700,000 with two-thirds the population) demonstrated untapped demand that applies to many markets, including Jamaica’s potential patient population.

From September 2019 CBD business profile through Delta-8 boom and bust, COVID community initiative, personal revelation of cannabis conviction, to “Renaissance” framing — Colin’s media trajectory mirrors trajectory of legal cannabis itself.

Our Philosophy — Four Core Principles

Our RSO is not traditional Rick Simpson Oil. It is formulated, multi-cannabinoid product informed by RSO tradition but departing from it in deliberate, evidence-motivated ways designed to solve problems that limited Simpson’s original vision.

1. Accessibility over gatekeeping
No medical card required. Anyone age 21+ can purchase. We ship nationwide across United States and internationally to customers who verify local legality. Simpson believed medicine should be accessible to everyone; we built product and distribution model that makes that accessible legally for Jamaican residents and diaspora communities worldwide.

2. Patient-controlled potency
THCa is sold in acidic, non-psychoactive form. You decide whether to use raw for non-psychoactive benefits or decarboxylate into delta-9 THC for full psychoactive potency. Simpson believed patients should control their medicine; we engineered product that puts that control in your hands through chemistry rather than rhetoric.

3. Open-source formulas
We publish complete formulas publicly — every cannabinoid, every milligram, every percentage — so anyone who cannot afford product can source ingredients and make their own version. Simpson gave his oil away free and taught people to make it; we adapted that ethos for modern cannabinoid marketplace by selling professionally manufactured product and publishing recipe.

4. Evidence-informed, not evidence-overstating
Our GENERAL KNOWLEDGE section represents our commitment to honest education about what science actually says. Simpson operated without access to peer-reviewed literature or clinical trial data; we have that access and use it to distinguish what is well-supported, what is emerging, and what is overstated.

Farm Bill Compliance and THCa Legal Framework

The 2018 Farm Bill legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at federal level in United States. This legal framework is foundation of our RSO product design.

Our RSO Sublingual Oil contains only 90mg delta-9 THC in entire 30mL bottle — 3mg per mL — well under 0.3% threshold. All cannabinoids are hemp-derived. Product is legal under federal law and in most states.

THCa — The Game-Changer
THCa is acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at point of sale because it has not been converted to delta-9 THC.

Practical significance is substantial. You can decarboxylate THCa into delta-9 THC at home by heating oil at 260°F (125°C) for 45-60 minutes in oven-safe glass container. This converts 1,500mg THCa into approximately 1,315mg delta-9 THC. Combined with existing 90mg delta-9 THC in formula, this produces approximately 1,405mg total delta-9 THC — giving product psychoactive potency comparable to traditional illegal RSO, entirely at your discretion after purchase.

This means same product can function as non-psychoactive anti-inflammatory (used raw) or full-potency psychoactive cannabinoid product (after home decarboxylation). You control the decision. Product is legal everywhere all component cannabinoids are legal, enabling international shipping to Jamaica and other jurisdictions where hemp-derived products with less than 0.3% delta-9 THC are permitted.

Important Legal Notice: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with local laws regarding cannabinoid products. We ship with full documentation, Certificates of Analysis, and receipts. International customers accept all customs and legal responsibility.

Open-Source Formulas — Why We Publish Everything

We publish complete RSO formulas publicly — every cannabinoid, every milligram amount, every percentage — in documents including this one. The RSO Sublingual Oil and RSO Vape Cartridge formulas are detailed fully in their respective sections.

Rationale is straightforward: if someone cannot afford our products — $129.99 for sublingual oil, $49.99 for vape cartridge — they can see exactly what formula contains, source individual cannabinoid distillates and isolates, and make their own version. The formulas in this document ARE the open-source formulas.

This is direct echo of Rick Simpson’s original ethos. Simpson gave his oil away free and taught people to make it. He never patented his method, never charged patients. We adapted that ethos for modern marketplace: sell professionally manufactured, lab-tested, standardized product for those who want it, and publish complete recipe for those who want to make it themselves.

As Colin said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

CBD Golden Paste Recipe — Our Original Open-Source Formula

The open-source philosophy didn’t start with RSO — it started with Bentley. On our About Us page, we published the actual CBD golden paste recipe that saved Bentley’s life, so any pet owner facing similar crisis can make it themselves:

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1-2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on pet size and needs; consult veterinarian)

Instructions:

1. Mix turmeric and water in saucepan over low heat, stirring continuously until thick paste forms (7-10 minutes). Add more water if too thick.
2. Add coconut oil and freshly ground black pepper, stir until thoroughly mixed.
3. Allow to cool, transfer to jar with lid, refrigerate up to two weeks.
4. Add small amount of CBD oil to paste before giving to pet, adjusting dosage based on weight and health needs. Start low and gradually increase.

Serving suggestion: Mix small amount of golden paste with pet’s food once or twice daily. Monitor pet for changes and consult veterinarian if concerns arise. Always consult veterinarian before starting new supplement regimen.

This recipe — published free, years before RSO formulas were open-sourced — demonstrates pattern is consistent. We gave away formula that saved Bentley before we gave away formula designed for people. Open-source ethos is not marketing strategy; it is foundational behavior of our company.

The Decarboxylation Choice — Patient-Controlled Potency

Traditional RSO was always fully decarboxylated. Heat of solvent evaporation converted all THCa into delta-9 THC, leaving patient with no choice about psychoactivity — oil was always psychoactive.

Our sublingual formula contains 1,500mg THCa in acidic, non-psychoactive form. This creates three distinct usage options:

Option 1 — Raw, no heat: All 1,500mg stays as THCa — completely non-psychoactive. THCa evidence describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism. This option is compatible with work, driving, and daytime use with zero psychoactive impairment.

Option 2 — Fully activated, home decarboxylation: Heat oil at 260°F (125°C) for 45-60 minutes in oven-safe glass container. Converts 1,500mg THCa to approximately 1,315mg delta-9 THC. Combined with existing 90mg delta-9 THC, yields ~1,405mg total delta-9 THC. Combined with 6,000mg delta-8 THC, activated product achieves psychoactive potency comparable to traditional illegal RSO — 100% legally, because decarboxylation occurs at your discretion after purchase. You may also transfer controlled portion from original bottle to second oven-safe container, decarboxylating only what you intend to use and preserving remainder in raw THCa form.

Option 3 — Vape, auto-decarboxylation: Our RSO Vape Cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is fastest-onset RSO delivery method available.

Conversion chemistry: THCa molecular weight is 358.47 g/mol. Conversion ratio is approximately 1mg THCa = 0.877mg delta-9 THC after decarboxylation, reflecting loss of CO₂ molecule during reaction.

This design puts potency decision entirely in your hands — aligning with Simpson’s principle that patients should control their medicine, but implementing it through actual product chemistry rather than one-size-fits-all approach.

Solvent-Free Production

Our RSO is not traditional extraction product. It is formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents present in finished product.

This approach eliminates residual solvent risk — one of most significant safety concerns with traditional RSO production. Product uses organic MCT oil (medium-chain triglycerides) as carrier base. MCT oil is food-grade lipid carrier facilitating cannabinoid absorption through sublingual tissue and providing neutral taste profile — significant improvement over tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through our website.

Our Complete Product Portfolio

Beyond RSO, we produce range of cannabinoid products, each developed from formulation knowledge Colin built over Bentley’s ten-year journey and his own PTSD/benzo withdrawal experience.

Asshole Peach — Our most popular product. Carefully formulated experience designed to provide euphoric, long-lasting sensation. Particularly favored by veterans for ability to relieve pain and PTSD symptoms without being overly aggressive.

Peace Gummies — Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. Formula also available in vape form for quick relief — Colin personally uses vape to manage his insomnia and severe PTSD ongoing.

Custom Creations — We offer custom-made products tailored to specific customer needs. Whether specific cannabinoid ratios, particular delivery formats, or formulations for unique health circumstances, we design targeted products on request. This includes formulations for vegans, diabetics, and those with specific dietary or health needs.

Our Two RSO Product Formats

RSO Sublingual Oil — $129.99

• 30mL bottle (1 fl oz)
• 16,590mg total cannabinoids (553mg per mL)
• Seven cannabinoids: CBD 4,500mg, CBG 3,000mg, delta-8 THC 6,000mg, THCa 1,500mg, delta-9 THC 90mg, CBN 750mg, CBC 750mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1mL increments
• Onset: 15-45 minutes (sublingual absorption through oral mucosa)
• Peak effects: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19% (sublingual route partially bypasses first-pass liver metabolism)
• Approximately 40-60 doses per bottle depending on serving size

RSO Vape Cartridge — $49.99

• 1-gram cartridge
• 900mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1-2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35% (variable, dependent on inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400-450°F)

Complete RSO Guide — Our full product guide with science, competitive analysis, protocols, and ordering information.

When to Use Each Format

Use Case	Recommended Format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability and discretion	Vape	Compact, no measuring required
Precise dosing control	Sublingual	Graduated dropper in 0.1mL increments
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive, zero impairment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

Competitive Comparison — OilWell RSO vs. Alternatives

OilWell RSO vs. Texas TCUP Dispensary RSO (e.g., Texas Original)

Dimension	TCUP Dispensary RSO	OilWell RSO
Cannabinoid profile	THC-only (~420mg THC per 0.5g syringe)	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG content	0mg	3,000mg
CBN content	0mg	750mg
CBC content	0mg	750mg
Patient-controlled potency	No — always fully psychoactive	Yes — THCa non-psychoactive until heated by customer
Access requirements	TCUP medical card with qualifying condition	Age 21+ only, no medical card required
Qualifying conditions	Cancer, PTSD, epilepsy, autism, terminal illness, ALS, MS, seizure disorders, incurable neurodegenerative diseases	None required
Delivery	Must travel to physical dispensary location	Same-day delivery Houston, nationwide and international shipping to Jamaica
Farm Bill compliant	No — state medical cannabis program	Yes — less than 0.3% delta-9 THC

OilWell RSO vs. Hemp CBD RSO (e.g., Lazarus Naturals)

Dimension	Lazarus Naturals RSO (10mL, 1,000mg)	OilWell RSO (30mL, 16,590mg)
Total cannabinoids	1,000mg	16,590mg
CBD content	~950mg	4,500mg
CBG content	15.5mg	3,000mg
CBN content	0.7mg	750mg
Delta-8 THC	0mg	6,000mg
THCa (convertible to delta-9 THC)	Minimal	1,500mg (converts to ~1,315mg delta-9 THC)
Psychoactive option	No meaningful psychoactive effect	Yes — via THCa decarboxylation and delta-8 THC
Approximate price	$40-50	$129.99

OilWell RSO vs. Traditional Illegal RSO — See Traditional RSO vs. Modern Formulated RSO table in previous section.

Condition-Specific Usage Context for Jamaican Patients

Important Disclaimer: Following usage contexts are informed by cannabinoid research cited in GENERAL KNOWLEDGE section and our formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, not substitute for professional medical care. These products have not been evaluated by Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult qualified healthcare provider before using cannabinoid products, especially if you have medical condition, are taking medications, are pregnant or nursing, or have health concerns. Do not operate vehicles or machinery while under influence of psychoactive cannabinoids.

For Jamaican cancer patients undergoing chemotherapy:

• Pre-chemo: 0.5-1.0mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0-2.0mL sublingual before bed (delivers 25-50mg CBN)
• Evidence context: delta-8 THC antiemetic evidence, delta-9 THC nausea/vomiting evidence, CBD anxiolytic buffering

For Jamaican chronic pain sufferers (fibromyalgia, arthritis, neuropathy, post-injury pain):

• Daytime: 0.3-0.5mL raw sublingual — provides anti-inflammatory cannabinoid exposure without psychoactive impairment, allowing you to work, drive, care for family
• Nighttime: 0.5-1.0mL decarboxylated sublingual — combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence context: CBD pain evidence, delta-9 THC pain evidence, beta-caryophyllene CB2 agonism, THCa COX-2 inhibition

For Jamaican patients with sleep disorders (insomnia, disrupted sleep from chronic pain or PTSD):

• Before bed: 1.0-2.0mL sublingual
• At 2.0mL, this delivers 50mg CBN — dosage level investigated in 2024 sleep literature
• At 1.0mL, this delivers 25mg CBN — above 20mg threshold associated with reduced sleep disturbance in published research
• Evidence context: CBN sleep evidence, cannabis and sleep review literature

For Jamaican anxiety and stress sufferers:

• Daytime functional relief: 0.3mL raw sublingual — CBD and CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0mL sublingual — full cannabinoid profile including CBN for sleep architecture
• Evidence context: CBD anxiety evidence, CBG pharmacology, limonene entourage-effect evidence

General titration principle for all Jamaican users: Start low, go slow. Begin with 0.25-0.5mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Delivery and Global Accessibility to Jamaica

We operate the only same-day RSO delivery system in Houston. Beyond Houston, we ship nationwide and internationally, including to Jamaica.

For Jamaican customers in Houston area:
If you’re part of Jamaican diaspora community in Houston, we offer same-day delivery:

• Texas Medical Center (FREE delivery) — all 60+ TMC institutions including MD Anderson, Memorial Hermann, Methodist, Texas Children’s, St. Luke’s
• Inner Loop (610) — Downtown, Midtown, Montrose, Heights, Rice Village, Museum District, River Oaks, Upper Kirby, Galleria ($5)
• Within Beltway 8 — Bellaire, Memorial, Spring Branch, South Houston, Pasadena, Hobby Airport area ($10)
• Greater Houston suburbs — Katy, Sugar Land, Pearland, Clear Lake, Woodlands, Cypress, Tomball, Humble, Kingwood ($15)
• Extended region (60 miles) — Galveston, Baytown, Rosenberg, Conroe, La Porte, Seabrook ($20-25)

Free delivery to Texas Medical Center — world’s largest medical complex with over 10 million patient visits annually — reflects our commitment to accessibility for patients who need it most, including Jamaican families seeking treatment at world-renowned cancer centers.

For Jamaican customers in United States:
We ship to all 50 states where Farm Bill-compliant products are legal:

• USPS Priority Mail (2-3 business days)
• FedEx and UPS Ground (3-5 business days)
• Discreet packaging with no cannabis branding visible
• Tracking provided for all orders
• Temperature-stable packaging for summer shipments
• Signature-required option available

For Jamaican customers in Jamaica and worldwide:
We ship internationally and have delivered to multiple countries across multiple continents. THCa legal framework makes this possible: because product contains less than 0.3% delta-9 THC at point of sale, it meets definition of hemp-derived product under 2018 Farm Bill and is shippable to jurisdictions with compatible hemp laws.

For Jamaican customers: All international packages include full documentation, Certificates of Analysis (COAs), and receipts for customs purposes. Minimum flat-fee shipping applies; excessive international shipping costs are billed to customer. Customer is responsible for verifying legality in their jurisdiction and accepts all customs and legal risk.

Contact for Jamaican orders: (832) 416-2816 or [email protected]

The significance for Jamaica: Rick Simpson could not ship his oil anywhere — it was Schedule I, illegal to produce, possess, or transport. A cancer patient in Kingston, a chronic pain sufferer in Montego Bay, a veteran with PTSD in Spanish Town, or a ganja advocate in Negril can now potentially access same clinical-strength multi-cannabinoid RSO formula that Houston resident receives via same-day delivery. We’ve built product that can move across borders legally — completing piece of Simpson’s vision that prohibition made impossible during his lifetime.

Our PANDEM1C SEO technology — proprietary system with 14 million distinct geopolitical locations in database and over 300 AI models — drives organic search visibility across six continents, making our products discoverable to Jamaican patients searching for RSO in English, Jamaican Patois search terms, and other languages.

GENERAL KNOWLEDGE — The Evidence Behind Every Compound

Research Method and Evidence Weighting

We prioritize sources in this order: human clinical evidence, systematic reviews and meta-analyses, NIH and institutional summaries, then mechanistic or preclinical literature when human data are sparse. This weighting matters because evidence base is not evenly distributed. Of compounds in our formula, CBD and delta-9 THC have strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still more dependent on reviews, animal work, and in vitro pharmacology.

Institutional Baseline from NIH and NCCIH

National Center for Complementary and Integrative Health states strongest established cannabinoid evidence is for:

• Certain rare epilepsies
• Chemotherapy-related nausea and vomiting
• Appetite and weight-loss indications associated with HIV/AIDS

NCCIH notes only modest evidence for chronic pain and multiple-sclerosis-related symptoms, with many other claimed uses still early-stage research.

Critical safety concerns highlighted by NIH:

• Impairment and motor vehicle crash risk
• Cannabis use disorder
• Pregnancy-related concerns
• Contamination or labeling inaccuracy
• THC-vape lung-injury concerns

NCCIH warns that over-the-counter CBD products may differ from labels and CBD itself has been associated with decreased alertness, gastrointestinal effects, liver-related adverse effects, and drug interactions.

Cannabinoid Evidence Profiles

CBD — Most Evidence-Developed Nonintoxicating Cannabinoid

• Best supported: Purified CBD has strongest human evidence in seizure disorders — clearest major-example indication acknowledged by institutional and peer-reviewed literature
• Anxiety: 2024 systematic review and meta-analysis covering 316 participants across eight eligible articles reported statistically significant anxiolytic signal, but authors stressed clinical sample remains limited and more trials needed before broad conclusions justified
• Pain: 2024 systematic review of clinical and preclinical CBD monotherapy studies concluded pain literature is promising but heterogeneous, with trial quality and consistency still limiting confidence in broad analgesic claims
• Sleep: 2023 insomnia review found literature remains methodologically weak, with many studies relying on nonvalidated subjective measures and relatively few objective sleep assessments
• Safety: 2023 systematic review and meta-analysis found real signal for liver enzyme elevation and possible drug-induced liver injury in some CBD contexts, especially relevant for concentrated oral products and polypharmacy settings

For Jamaican patients: CBD is the cannabinoid we can discuss with most confidence for seizure disorders. For anxiety, pain, and sleep, evidence is promising but requires cautious interpretation. If you’re managing multiple medications (common among Jamaican elders and chronic disease patients), CBD’s drug interaction potential requires medical supervision.

CBG — Promising Minor Cannabinoid, Limited Clinical Validation

• Evidence profile: Mostly review-level and preclinical; human evidence remains sparse
• Pharmacology: CBG is biosynthetic precursor to several major cannabinoids with pharmacologically distinct profile spanning cannabinoid receptors, alpha-2 adrenoceptors, and 5-HT1A-related signaling
• Potential research areas: Neurologic disorders, inflammatory bowel disease, antibacterial activity — primarily pharmacology-led hypotheses or preclinical findings rather than mature human therapeutic conclusions
• Caution: CBG is already being sold commercially while evidence base remains thin, meaning claims frequently outrun science

For Jamaican IBS/ulcerative colitis patients: CBG’s preclinical gut anti-inflammatory signals are interesting but not yet proven in humans. We include 3,000mg in our formula because of this promise, not because of proven efficacy.

Delta-8 THC — Pharmacologically Relevant but Less Clinically Characterized

• Evidence profile: Pharmacologically relevant, psychoactive, much less clinically characterized than delta-9 THC
• Comparative pharmacology: 2022 review concluded delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 THC is partial CB1 agonist with cannabimimetic activity in animals and humans, but appears less potent than delta-9 THC, likely due to weaker CB1 affinity
• Public health: 2023 scoping review found delta-8 evidence base dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials. Review noted reports of adverse consequences and emphasized regulatory and product-quality concerns
• Manufacturing: Recent chemistry and pharmacology review reinforces commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels, which is why product-byproduct and lab-testing questions matter

For Jamaican users: Delta-8 THC should be treated as psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many realize. The 6,000mg in our formula is substantial — we include it for therapeutic reasons, not just as filler.

THCa — Important Chemically, Limited Direct Human Evidence

• What it is: Acidic precursor of THC, may represent very large share of THC-related content in raw plant material
• Key formulation issue: THCa decarboxylates into THC during heating and can change over time during storage and processing
• Psychoactivity: Major review stresses THCa itself does not produce psychoactive effects associated with THC in humans, but distinction only holds if molecule stays in acidic form and is not substantially decarboxylated
• Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but not equivalent to established human outcomes

For Jamaican users: THCa is best understood as highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage. Our formula’s 1,500mg gives you flexibility to use non-psychoactively or convert to THC at home.

Delta-9 THC — Strongest Human Evidence of Psychoactive Cannabinoids, But Clearest Adverse-Effect Burden

• Institutionally best supported: NCCIH identifies THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea/vomiting, appetite/weight loss in HIV/AIDS, and some multiple-sclerosis- and pain-related outcomes, while stressing many other uses remain uncertain or early-stage
• Pain evidence: 2022 systematic review of cannabis-based products for chronic pain found products with high THC content or comparable THC:CBD ratios may provide short-term pain benefit, but also increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events
• Pharmacokinetics: Inhaled THC produces effects within seconds to minutes, peaks ~15-30 minutes, tapers over few hours; oral THC has later onset, later peak, longer duration, which matters for both benefit and overconsumption risk
• Mental health risk: 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis or schizophrenia outcomes and cannabis use disorder, with concerning signals for anxiety and depression in nontherapeutic settings
• Broader safety: Anxiety or panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, vape-related lung-injury concerns

For Jamaican patients: Delta-9 THC has legitimate therapeutic relevance in some settings, but also carries clearest intoxication, psychiatric, and dose-related safety liabilities. Our formula contains only 90mg total delta-9 THC (3mg/mL) — dramatically lower than Simpson’s protocol delivering 600-900mg daily. This is intentional harm-reduction design.

CBN — Reputation Stronger Than Evidence

• What marketed for: Sleep and sedation. That reputation is widespread, but clinical support is far thinner than market suggests
• Best direct review: 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims
• Broader sleep literature: 2024 updated review on cannabis and sleep concluded overall cannabinoid sleep research still doesn’t match scale of real-world use, and need for better-designed, adequately powered trials remains substantial
• Chemical context: Downstream cannabinoid degradation pathways matter; THC can further degrade toward CBN under certain conditions, which helps explain why CBN is often discussed in aging or oxidized cannabis chemistry contexts

For Jamaican insomniacs: CBN is clearest example where cultural reputation outpaces clinical evidence. We include 750mg because of promising preclinical work and patient interest, not because of proven efficacy. Our formula’s 25-50mg CBN at typical doses aligns with dosages being investigated in emerging research.

CBC — Emerging, Intriguing, Overwhelmingly Preclinical

• Pharmacology: 2024 focused review argues CBC has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, highlighting antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets
• Older literature: Anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, possible neurobiological or antiproliferative relevance — but not yet strong evidence for patient-facing claims
• Safety caveat: 2024 CBC review explicitly notes over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety

For Jamaican research-aware patients: CBC belongs in category of scientifically credible minor cannabinoids deserving more research, not already-validated clinical actives. Our 750mg inclusion is forward-looking, not backward-proven.

Terpene Evidence Profiles

Important framing for Jamaican users: Terpene claims need even stricter interpretation than cannabinoid claims. Much literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than controlled human studies of cannabis formulations. 2024 entourage-effect review makes this especially important: terpene bioactivity is plausible and sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited.

Limonene — Multifunctional But Not Cannabis-Specific

• Potential activity: 2021 review describes limonene as multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory possibilities, but overwhelming share of claims comes from nonhuman or non-cannabis literature
• Safety note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens important in patch-testing literature

For Jamaican citrus lovers: Limonene is biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly supported in humans. The citrus brightness in our terpene profile is sensory delight, not proven therapy.

Myrcene — Preclinical Promise, Limited Human Proof

• Research summary: 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, analgesic properties and discusses possible mechanisms, but explicitly states human studies are lacking
• Interpretation caution: Myrcene is often invoked as if it were proven sedating terpene explaining couch-lock or sleep effects. This is stronger claim than human evidence currently supports

For Jamaican relaxation seekers: Myrcene is plausible bioactive terpene, but compound-specific clinical claims about mood, pain, or sedation remain far ahead of definitive human proof.

Caryophyllene — The CB2 Agonist Standout

• Why it stands out: 2021 focused review describes beta-caryophyllene as selective CB2 receptor agonist, unusual and especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms
• Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective actions repeatedly discussed, but human clinical confirmation remains limited

For Jamaican inflammation sufferers: Beta-caryophyllene is strongest candidate for terpene with cannabinoid-system significance, but still should not be described as clinically proven for outcomes commonly attributed to it.

Pinene — Brain Health Hypotheses Not Yet Proven

• Brain-health framing: 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, neuroprotective signals justifying future study, but emphasized evidence is mostly preclinical and well-designed clinical trials are lacking
• Interpretation caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts

Linalool — Similar Profile to Pinene

• Research summary: Repeatedly discussed in relation to stress, mood, brain-health pharmacology. 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological and psychiatric contexts, while still emphasizing lack of robust human trials
• Additional literature: Separate review discusses possible antidepressant mechanisms and neuropharmacologic relevance, but remains translational rather than definitive clinical story
• Safety note: As with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature

Humulene — Cannabimimetic Properties But Early

• Scoping-review findings: 2024 scoping review analyzed 340 articles and found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work even suggesting cannabimimetic properties via CB1 and adenosine A2a pathways
• Interpretation caution: Findings are valuable for hypothesis generation, but do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes

Terpinolene — Least Clinically Characterized

• Systematic-review findings: 2021 terpinolene review screened 2,449 records, included 57 studies, concluding terpinolene has range of reported biological effects but evidence base is still dominated by in silico, in vitro, and animal studies rather than human trials
• Interpretation caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not as established compound-specific clinical effects

Research Limits and Interpretation Rules

1. Evidence base is highly uneven. CBD and delta-9 THC can support most detailed human-facing statements; the rest require more caution.
2. Data categories aren’t interchangeable. Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable. One common error is letting evidence from one category stand in for another.
3. Minor cannabinoids are commercially interesting BECAUSE they’re underexplored, but that also means claims around them often become inflated.
4. Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect interpretation in real-world products.
5. For THCa in particular, chemistry is destiny: Storage and heating can change actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC.

Common Overstatements to Avoid

Overstatement: CBN is clinically proven sleep cannabinoid.
More accurate: Specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified.

Overstatement: Myrcene is proven human sedative that reliably explains couch-lock.
More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited.

Overstatement: Terpenes in general have proven entourage effects in patients.
More accurate: Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific.

Overstatement: THCa is always nonpsychoactive.
More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing effective exposure.

Overstatement: Delta-8 THC is safe because it is hemp-derived.
More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns.

Practical Takeaways for Our Formulas

• Most evidence-developed actives: CBD and delta-9 THC
• Delta-8 THC is not trivial or purely mild ingredient; it is psychoactive cannabinoid with less robust safety and efficacy characterization than delta-9 THC
• THCa meaningfully changes with processing and should not be interpreted same way in raw, gently handled, and heated formats
• CBG, CBN, CBC are scientifically credible but clinically immature compared with CBD and THC
• Listed terpenes are likely highly relevant to aroma, flavor, and potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported

Our RSO Sublingual Oil Formula

Cannabinoid	Amount (mg)	% of Total
CBD	4,500	27.1%
CBG	3,000	18.1%
Delta-8 THC	6,000	36.2%
THCa	1,500	9.0%
Delta-9 THC	90	0.5%
CBN	750	4.5%
CBC	750	4.5%
Total	16,590	100%

Additional specifications:

• Active cannabinoids per mL: 553mg
• Live terpenes: 5%
• Carrier: Organic MCT oil
• Format: 30mL bottle with graduated dropper (0.1mL increments)
• Onset: 15-45 minutes
• Duration: 4-6 hours
• Bioavailability: 13-19%
• Doses per bottle: 40-60 depending on serving size

What this means for Jamaican users: This is clinical-strength formulation. At 553mg/mL, it’s one of most concentrated legal cannabinoid products available. The 16,590mg total means you’re getting substantial amounts of seven different cannabinoids, each at levels that match or exceed dosages used in published research. This isn’t diluted CBD oil — this is full-spectrum, research-informed RSO designed for serious therapeutic use.

Our RSO Vape Cartridge Formula

Cannabinoid	Percentage	Approx. mg per gram
CBD	30%	300mg
CBG	20%	200mg
Delta-8 THC	15%	150mg
THCa	10%	100mg
CBN	10%	100mg
CBC	10%	100mg
Total	95%	~950mg

Additional specifications:

• Live terpenes: 5%+
• Format: 1-gram cartridge
• Thread: 510 universal battery compatibility
• Onset: 1-2 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35%
• Auto-decarboxylation: THCa converts to delta-9 THC at vaping temperature (400-450°F)

What this means for Jamaican users: This is our fast-acting format. When you need immediate relief from breakthrough pain, panic attack, or acute nausea, the vape delivers cannabinoids to bloodstream within 1-2 minutes. The auto-decarboxylation means every puff gives you freshly activated THC alongside other cannabinoids. Keep this in your pocket for emergencies while using sublingual oil for daily maintenance.

Terpene Profile (Both Products)

• Limonene — Citrus-bright notes
• Myrcene — Earthy foundation
• Caryophyllene (β-caryophyllene) — Pepper/spice character
• Pinene — Forest-fresh aroma
• Linalool — Floral, lavender notes
• Humulene — Earthy, woody undertones
• Terpinolene — Piney, fruity, sparkling finish

Overall sensory experience: The terpene blend creates complex, layered aroma and flavor profile that evolves as product warms under tongue or in vape device. For Jamaican users familiar with traditional ganja aromas, you’ll recognize some elements while appreciating the refined, non-combustion delivery. The terpenes aren’t just for smell — they’re included at 5% because of plausible bioactivity via entourage effect, even though robust human clinical proof remains limited.

How Our Formulas Connect to Evidence in This Document

Every cannabinoid in our formula — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC — has its own evidence profile in GENERAL KNOWLEDGE section. Every terpene — limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene — is covered with preclinical and review-level evidence.

The formulas published here are anchored to per-compound evidence summaries that explain what is well-supported by human clinical data, what is emerging from review and preclinical literature, and what is overstated relative to current evidence base. Where our RSO guide page makes specific research claims about individual cannabinoids or terpenes, this document provides source evaluation context — same peer-reviewed citations, same evidence-tier assessments, same cautious interpretation framework.

Our evidence hierarchy, overstatement warnings, and safety notes apply equally to our own products. We do not exempt ourselves from same evidence standards applied to broader cannabinoid field. That is intentional. Our position — as stated by Colin Valencia in 2019 — is that people deserve best possible version of information so they can give it fair shot and decide for themselves whether it is right or wrong for them.

For Jamaican readers: This is our promise to you — we hold ourselves to same rigorous evidence standards we apply to everyone else. In a market where exaggerated claims are common, we’re giving you the actual science, the actual formulas, and the honest assessment of what we know and don’t know.

Ordering Information for Jamaican Customers

RSO Sublingual Oil: $129.99 (30mL, 16,590mg total cannabinoids)
RSO Vape Cartridge: $49.99 (1g, ~900mg total cannabinoids)

How to order from Jamaica:

1. Visit our website: https://oilwellcbd.com/thca-rick-simpson-oil-rso-by-oilwell-cannabis-of-houston-texas/
2. Verify Jamaican hemp product import laws are compatible with Farm Bill-compliant products
3. Place order and select international shipping
4. We provide full COAs, customs documentation, and receipts
5. Accept delivery and verify product integrity

Contact us:
Phone: (832) 416-2816
Email: [email protected]
Instagram: @oilwellcbd
Address: 810 Richmond Ave, Houston, TX 77006 (Montrose neighborhood)

Business hours (Houston time):
Monday-Thursday: 10:00 AM – 7:00 PM
Friday-Saturday: 10:00 AM – 10:00 PM
Sunday: 10:00 AM – 4:00 PM

For Jamaican diaspora in Houston: Visit our Montrose location to see products, talk with our team, and experience the same-day delivery service that has made us Houston’s trusted cannabis source.

Final Thoughts for Our Jamaican Community

Rick Simpson’s story began with a man who was failed by the medical system and found his own path. Colin Valencia’s story began with a dog who was failed by veterinary medicine and found cannabinoid salvation. These parallel origins reflect a universal truth: when conventional care falls short, cannabis offers hope.

But hope without honesty is just hype. That’s why we’ve published this complete document — every formula, every evidence assessment, every safety concern, every limitation of what we know. We believe Jamaican patients, caregivers, and healthcare providers deserve nothing less.

Whether you’re in Kingston dealing with chronic pain that keeps you from enjoying the beaches, in Montego Bay managing chemotherapy side effects, in Spanish Town struggling with PTSD, or in rural Jamaica seeking alternatives to expensive pharmaceuticals — we see you. We respect your need for honest information. We respect your right to make informed decisions about your health. And we respect your intelligence enough to give you the full picture, not a sales pitch.

The open-source formulas are here for anyone who needs them. The evidence is here for anyone who wants to evaluate it. The products are here for anyone who chooses to purchase them. And our team is here for anyone who has questions.

We’re OilWell Cannabis. We’re Houston-based. We’re evidence-grounded. And we’re here for Jamaica.

---